id	sid	tid	token	lemma	pos
ajst-17673	1	1	academic	academic	ADJ
ajst-17673	1	2	journal	journal	NOUN
ajst-17673	1	3	of	of	ADP
ajst-17673	1	4	science	science	NOUN
ajst-17673	1	5	and	and	CCONJ
ajst-17673	1	6	technology	technology	NOUN
ajst-17673	1	7	issn	issn	NOUN
ajst-17673	1	8	:	:	PUNCT
ajst-17673	1	9	2771	2771	NUM
ajst-17673	1	10	-	-	SYM
ajst-17673	1	11	3032	3032	NUM
ajst-17673	1	12	|	|	NOUN
ajst-17673	1	13	vol	vol	NOUN
ajst-17673	1	14	.	.	PROPN
ajst-17673	2	1	9	9	NUM
ajst-17673	2	2	,	,	PUNCT
ajst-17673	2	3	no	no	INTJ
ajst-17673	2	4	.	.	NOUN
ajst-17673	2	5	2	2	NUM
ajst-17673	2	6	,	,	PUNCT
ajst-17673	2	7	2024	2024	NUM
ajst-17673	2	8	94	94	NUM
ajst-17673	2	9	comparison	comparison	NOUN
ajst-17673	2	10	of	of	ADP
ajst-17673	2	11	the	the	DET
ajst-17673	2	12	efficacy	efficacy	NOUN
ajst-17673	2	13	and	and	CCONJ
ajst-17673	2	14	safety	safety	NOUN
ajst-17673	2	15	of	of	ADP
ajst-17673	2	16	cyp2c19	cyp2c19	NOUN
ajst-17673	2	17	gene‐	gene‐	ADP
ajst-17673	2	18	guided	guide	VERB
ajst-17673	2	19	oral	oral	ADJ
ajst-17673	2	20	administration	administration	NOUN
ajst-17673	2	21	of	of	ADP
ajst-17673	2	22	different	different	ADJ
ajst-17673	2	23	p2y12	p2y12	PROPN
ajst-17673	2	24	inhibitors	inhibitor	NOUN
ajst-17673	2	25	in	in	ADP
ajst-17673	2	26	elderly	elderly	ADJ
ajst-17673	2	27	patients	patient	NOUN
ajst-17673	2	28	with	with	ADP
ajst-17673	2	29	acute	acute	ADJ
ajst-17673	2	30	coronary	coronary	ADJ
ajst-17673	2	31	syndrome	syndrome	NOUN
ajst-17673	2	32	binbin	binbin	PROPN
ajst-17673	2	33	zhen1	zhen1	PROPN
ajst-17673	2	34	,	,	PUNCT
ajst-17673	2	35	jianhua	jianhua	PROPN
ajst-17673	2	36	zhang1	zhang1	PROPN
ajst-17673	2	37	,	,	PUNCT
ajst-17673	2	38	*	*	PROPN
ajst-17673	2	39	1department	1department	NUM
ajst-17673	2	40	of	of	ADP
ajst-17673	2	41	cardiology	cardiology	NOUN
ajst-17673	2	42	,	,	PUNCT
ajst-17673	2	43	the	the	DET
ajst-17673	2	44	first	first	ADJ
ajst-17673	2	45	affiliated	affiliated	ADJ
ajst-17673	2	46	hospital	hospital	NOUN
ajst-17673	2	47	of	of	ADP
ajst-17673	2	48	jinan	jinan	PROPN
ajst-17673	2	49	university	university	PROPN
ajst-17673	2	50	,	,	PUNCT
ajst-17673	2	51	guangzhou	guangzhou	PROPN
ajst-17673	2	52	510630	510630	NUM
ajst-17673	2	53	,	,	PUNCT
ajst-17673	2	54	china	china	PROPN
ajst-17673	2	55	*	*	PUNCT
ajst-17673	2	56	corresponding	correspond	VERB
ajst-17673	2	57	author	author	NOUN
ajst-17673	2	58	:	:	PUNCT
ajst-17673	2	59	jianhua	jianhua	PROPN
ajst-17673	2	60	zhang	zhang	PROPN
ajst-17673	2	61	(	(	PUNCT
ajst-17673	2	62	email	email	NOUN
ajst-17673	2	63	:	:	PUNCT
ajst-17673	2	64	463967874@qq.com	463967874@qq.com	NUM
ajst-17673	2	65	)	)	PUNCT
ajst-17673	2	66	abstract	abstract	NOUN
ajst-17673	2	67	:	:	PUNCT
ajst-17673	2	68	objective	objective	NOUN
ajst-17673	2	69	to	to	PART
ajst-17673	2	70	explore	explore	VERB
ajst-17673	2	71	the	the	DET
ajst-17673	2	72	survival	survival	NOUN
ajst-17673	2	73	prognosis	prognosis	NOUN
ajst-17673	2	74	and	and	CCONJ
ajst-17673	2	75	safety	safety	NOUN
ajst-17673	2	76	analysis	analysis	NOUN
ajst-17673	2	77	of	of	ADP
ajst-17673	2	78	the	the	DET
ajst-17673	2	79	cyp2c19	cyp2c19	NOUN
ajst-17673	2	80	gene	gene	NOUN
ajst-17673	2	81	-	-	PUNCT
ajst-17673	2	82	guided	guide	VERB
ajst-17673	2	83	acs	acs	NOUN
ajst-17673	2	84	elderly	elderly	ADJ
ajst-17673	2	85	patient	patient	NOUN
ajst-17673	2	86	group	group	NOUN
ajst-17673	2	87	using	use	VERB
ajst-17673	2	88	tegretol	tegretol	NOUN
ajst-17673	2	89	and	and	CCONJ
ajst-17673	2	90	clopidogrel	clopidogrel	NOUN
ajst-17673	2	91	.	.	PUNCT
ajst-17673	3	1	methods	method	NOUN
ajst-17673	3	2	three	three	NUM
ajst-17673	3	3	hundred	hundred	NUM
ajst-17673	3	4	and	and	CCONJ
ajst-17673	3	5	eighty	eighty	NUM
ajst-17673	3	6	-	-	PUNCT
ajst-17673	3	7	five	five	NUM
ajst-17673	3	8	acs	acs	NOUN
ajst-17673	3	9	patients	patient	NOUN
ajst-17673	3	10	aged	age	VERB
ajst-17673	3	11	≥65	≥65	NUM
ajst-17673	3	12	years	year	NOUN
ajst-17673	3	13	were	be	AUX
ajst-17673	3	14	selected	select	VERB
ajst-17673	3	15	,	,	PUNCT
ajst-17673	3	16	tested	test	VERB
ajst-17673	3	17	for	for	ADP
ajst-17673	3	18	polymorphisms	polymorphism	NOUN
ajst-17673	3	19	in	in	ADP
ajst-17673	3	20	the	the	DET
ajst-17673	3	21	cyp2c19	cyp2c19	NOUN
ajst-17673	3	22	gene	gene	NOUN
ajst-17673	3	23	,	,	PUNCT
ajst-17673	3	24	and	and	CCONJ
ajst-17673	3	25	divided	divide	VERB
ajst-17673	3	26	into	into	ADP
ajst-17673	3	27	two	two	NUM
ajst-17673	3	28	groups	group	NOUN
ajst-17673	3	29	according	accord	VERB
ajst-17673	3	30	to	to	ADP
ajst-17673	3	31	the	the	DET
ajst-17673	3	32	oral	oral	ADJ
ajst-17673	3	33	p2y12	p2y12	NOUN
ajst-17673	3	34	receptor	receptor	NOUN
ajst-17673	3	35	inhibitor	inhibitor	NOUN
ajst-17673	3	36	:	:	PUNCT
ajst-17673	3	37	320	320	NUM
ajst-17673	3	38	patients	patient	NOUN
ajst-17673	3	39	in	in	ADP
ajst-17673	3	40	the	the	DET
ajst-17673	3	41	clopidogrel	clopidogrel	NOUN
ajst-17673	3	42	group	group	NOUN
ajst-17673	3	43	and	and	CCONJ
ajst-17673	3	44	165	165	NUM
ajst-17673	3	45	patients	patient	NOUN
ajst-17673	3	46	in	in	ADP
ajst-17673	3	47	the	the	DET
ajst-17673	3	48	tegretol	tegretol	PROPN
ajst-17673	3	49	group	group	NOUN
ajst-17673	3	50	.	.	PUNCT
ajst-17673	4	1	patients	patient	NOUN
ajst-17673	4	2	were	be	AUX
ajst-17673	4	3	followed	follow	VERB
ajst-17673	4	4	up	up	ADP
ajst-17673	4	5	for	for	ADP
ajst-17673	4	6	1	1	NUM
ajst-17673	4	7	year	year	NOUN
ajst-17673	4	8	after	after	ADP
ajst-17673	4	9	discharge	discharge	NOUN
ajst-17673	4	10	from	from	ADP
ajst-17673	4	11	the	the	DET
ajst-17673	4	12	hospital	hospital	NOUN
ajst-17673	4	13	,	,	PUNCT
ajst-17673	4	14	with	with	ADP
ajst-17673	4	15	the	the	DET
ajst-17673	4	16	primary	primary	ADJ
ajst-17673	4	17	end	end	NOUN
ajst-17673	4	18	point	point	NOUN
ajst-17673	4	19	being	be	AUX
ajst-17673	4	20	a	a	DET
ajst-17673	4	21	composite	composite	ADJ
ajst-17673	4	22	end	end	NOUN
ajst-17673	4	23	point	point	NOUN
ajst-17673	4	24	of	of	ADP
ajst-17673	4	25	adverse	adverse	ADJ
ajst-17673	4	26	cardiovascular	cardiovascular	ADJ
ajst-17673	4	27	events	event	NOUN
ajst-17673	4	28	including	include	VERB
ajst-17673	4	29	cardiac	cardiac	ADJ
ajst-17673	4	30	death	death	NOUN
ajst-17673	4	31	,	,	PUNCT
ajst-17673	4	32	nonfatal	nonfatal	ADJ
ajst-17673	4	33	infarction	infarction	NOUN
ajst-17673	4	34	,	,	PUNCT
ajst-17673	4	35	or	or	CCONJ
ajst-17673	4	36	absence	absence	NOUN
ajst-17673	4	37	of	of	ADP
ajst-17673	4	38	stroke	stroke	NOUN
ajst-17673	4	39	,	,	PUNCT
ajst-17673	4	40	and	and	CCONJ
ajst-17673	4	41	the	the	DET
ajst-17673	4	42	secondary	secondary	ADJ
ajst-17673	4	43	end	end	NOUN
ajst-17673	4	44	point	point	NOUN
ajst-17673	4	45	including	include	VERB
ajst-17673	4	46	unstable	unstable	ADJ
ajst-17673	4	47	angina	angina	NOUN
ajst-17673	4	48	,	,	PUNCT
ajst-17673	4	49	in	in	ADP
ajst-17673	4	50	-	-	PUNCT
ajst-17673	4	51	stent	stent	NOUN
ajst-17673	4	52	stenosis	stenosis	NOUN
ajst-17673	4	53	,	,	PUNCT
ajst-17673	4	54	target	target	NOUN
ajst-17673	4	55	vessel	vessel	NOUN
ajst-17673	4	56	revascularization	revascularization	NOUN
ajst-17673	4	57	,	,	PUNCT
ajst-17673	4	58	and	and	CCONJ
ajst-17673	4	59	all	all	DET
ajst-17673	4	60	-	-	PUNCT
ajst-17673	4	61	cause	cause	NOUN
ajst-17673	4	62	mortality	mortality	NOUN
ajst-17673	4	63	,	,	PUNCT
ajst-17673	4	64	as	as	ADV
ajst-17673	4	65	well	well	ADV
ajst-17673	4	66	as	as	ADP
ajst-17673	4	67	bleeding	bleed	VERB
ajst-17673	4	68	events	event	NOUN
ajst-17673	4	69	.	.	PUNCT
ajst-17673	5	1	results	result	VERB
ajst-17673	5	2	the	the	DET
ajst-17673	5	3	1	1	NUM
ajst-17673	5	4	-	-	PUNCT
ajst-17673	5	5	year	year	NOUN
ajst-17673	5	6	rate	rate	NOUN
ajst-17673	5	7	of	of	ADP
ajst-17673	5	8	ischemic	ischemic	ADJ
ajst-17673	5	9	events	event	NOUN
ajst-17673	5	10	was	be	AUX
ajst-17673	5	11	lower	low	ADJ
ajst-17673	5	12	in	in	ADP
ajst-17673	5	13	patients	patient	NOUN
ajst-17673	5	14	treated	treat	VERB
ajst-17673	5	15	with	with	ADP
ajst-17673	5	16	tegretol	tegretol	NOUN
ajst-17673	5	17	compared	compare	VERB
ajst-17673	5	18	with	with	ADP
ajst-17673	5	19	the	the	DET
ajst-17673	5	20	clopidogrel	clopidogrel	NOUN
ajst-17673	5	21	group	group	NOUN
ajst-17673	6	1	[	[	X
ajst-17673	6	2	28.5	28.5	NUM
ajst-17673	6	3	%	%	NOUN
ajst-17673	6	4	(	(	PUNCT
ajst-17673	6	5	47/165	47/165	NUM
ajst-17673	6	6	)	)	PUNCT
ajst-17673	6	7	versus	versus	ADP
ajst-17673	6	8	26.3	26.3	NUM
ajst-17673	6	9	%	%	NOUN
ajst-17673	6	10	(	(	PUNCT
ajst-17673	6	11	84/320	84/320	NUM
ajst-17673	6	12	)	)	PUNCT
ajst-17673	6	13	,	,	PUNCT
ajst-17673	6	14	p	p	X
ajst-17673	7	1	=	=	PROPN
ajst-17673	7	2	0.599	0.599	NUM
ajst-17673	7	3	]	]	PUNCT
ajst-17673	7	4	,	,	PUNCT
ajst-17673	7	5	and	and	CCONJ
ajst-17673	7	6	the	the	DET
ajst-17673	7	7	difference	difference	NOUN
ajst-17673	7	8	in	in	ADP
ajst-17673	7	9	the	the	DET
ajst-17673	7	10	1	1	NUM
ajst-17673	7	11	-	-	PUNCT
ajst-17673	7	12	year	year	NOUN
ajst-17673	7	13	rate	rate	NOUN
ajst-17673	7	14	of	of	ADP
ajst-17673	7	15	barc	barc	PROPN
ajst-17673	7	16	2	2	NUM
ajst-17673	7	17	,	,	PUNCT
ajst-17673	7	18	3	3	NUM
ajst-17673	7	19	,	,	PUNCT
ajst-17673	7	20	and	and	CCONJ
ajst-17673	7	21	5	5	NUM
ajst-17673	7	22	events	event	NOUN
ajst-17673	7	23	between	between	ADP
ajst-17673	7	24	the	the	DET
ajst-17673	7	25	two	two	NUM
ajst-17673	7	26	groups	group	NOUN
ajst-17673	7	27	was	be	AUX
ajst-17673	7	28	not	not	PART
ajst-17673	7	29	statistically	statistically	ADV
ajst-17673	7	30	significant	significant	ADJ
ajst-17673	8	1	[	[	PUNCT
ajst-17673	8	2	6.0	6.0	NUM
ajst-17673	8	3	%	%	NOUN
ajst-17673	8	4	(	(	PUNCT
ajst-17673	8	5	10/165	10/165	NUM
ajst-17673	8	6	)	)	PUNCT
ajst-17673	8	7	versus	versus	ADP
ajst-17673	8	8	3.4	3.4	NUM
ajst-17673	8	9	%	%	NOUN
ajst-17673	8	10	(	(	PUNCT
ajst-17673	8	11	11/320	11/320	NUM
ajst-17673	8	12	)	)	PUNCT
ajst-17673	8	13	,	,	PUNCT
ajst-17673	8	14	p	p	X
ajst-17673	8	15	=	=	NOUN
ajst-17673	8	16	0.179	0.179	NUM
ajst-17673	8	17	]	]	PUNCT
ajst-17673	8	18	.	.	PUNCT
ajst-17673	9	1	p	p	X
ajst-17673	9	2	=	=	NOUN
ajst-17673	9	3	0.179	0.179	NUM
ajst-17673	9	4	]	]	PUNCT
ajst-17673	9	5	.	.	PUNCT
ajst-17673	10	1	conclusion	conclusion	NOUN
ajst-17673	10	2	in	in	ADP
ajst-17673	10	3	elderly	elderly	ADJ
ajst-17673	10	4	patients	patient	NOUN
ajst-17673	10	5	with	with	ADP
ajst-17673	10	6	cyp2c19	cyp2c19	NOUN
ajst-17673	10	7	-	-	PUNCT
ajst-17673	10	8	directed	direct	VERB
ajst-17673	10	9	acs	ac	NOUN
ajst-17673	10	10	,	,	PUNCT
ajst-17673	10	11	there	there	PRON
ajst-17673	10	12	was	be	VERB
ajst-17673	10	13	no	no	DET
ajst-17673	10	14	significant	significant	ADJ
ajst-17673	10	15	difference	difference	NOUN
ajst-17673	10	16	in	in	ADP
ajst-17673	10	17	survival	survival	NOUN
ajst-17673	10	18	prognosis	prognosis	NOUN
ajst-17673	10	19	,	,	PUNCT
ajst-17673	10	20	ischemic	ischemic	ADJ
ajst-17673	10	21	events	event	NOUN
ajst-17673	10	22	,	,	PUNCT
ajst-17673	10	23	or	or	CCONJ
ajst-17673	10	24	bleeding	bleed	VERB
ajst-17673	10	25	risk	risk	NOUN
ajst-17673	10	26	between	between	ADP
ajst-17673	10	27	tegretol	tegretol	NOUN
ajst-17673	10	28	and	and	CCONJ
ajst-17673	10	29	clopidogrel	clopidogrel	NOUN
ajst-17673	10	30	at	at	ADP
ajst-17673	10	31	1	1	NUM
ajst-17673	10	32	year	year	NOUN
ajst-17673	10	33	.	.	PUNCT
ajst-17673	11	1	keywords	keyword	NOUN
ajst-17673	11	2	:	:	PUNCT
ajst-17673	11	3	acute	acute	ADJ
ajst-17673	11	4	coronary	coronary	ADJ
ajst-17673	11	5	syndrome	syndrome	NOUN
ajst-17673	11	6	,	,	PUNCT
ajst-17673	11	7	cyp2c19	cyp2c19	NOUN
ajst-17673	11	8	gene	gene	NOUN
ajst-17673	11	9	,	,	PUNCT
ajst-17673	11	10	clopidogrel	clopidogrel	NOUN
ajst-17673	11	11	,	,	PUNCT
ajst-17673	11	12	tegretol	tegretol	NOUN
ajst-17673	11	13	,	,	PUNCT
ajst-17673	11	14	ischemic	ischemic	ADJ
ajst-17673	11	15	events	event	NOUN
ajst-17673	11	16	.	.	PUNCT
ajst-17673	12	1	1	1	X
ajst-17673	12	2	.	.	X
ajst-17673	12	3	introduction	introduction	NOUN
ajst-17673	12	4	coronary	coronary	ADJ
ajst-17673	12	5	heart	heart	NOUN
ajst-17673	12	6	disease	disease	NOUN
ajst-17673	12	7	(	(	PUNCT
ajst-17673	12	8	chd	chd	NOUN
ajst-17673	12	9	)	)	PUNCT
ajst-17673	12	10	is	be	AUX
ajst-17673	12	11	a	a	DET
ajst-17673	12	12	common	common	ADJ
ajst-17673	12	13	chronic	chronic	ADJ
ajst-17673	12	14	disease	disease	NOUN
ajst-17673	12	15	with	with	ADP
ajst-17673	12	16	a	a	DET
ajst-17673	12	17	high	high	ADJ
ajst-17673	12	18	rate	rate	NOUN
ajst-17673	12	19	of	of	ADP
ajst-17673	12	20	sudden	sudden	ADJ
ajst-17673	12	21	death	death	NOUN
ajst-17673	12	22	and	and	CCONJ
ajst-17673	12	23	serious	serious	ADJ
ajst-17673	12	24	harm	harm	NOUN
ajst-17673	12	25	,	,	PUNCT
ajst-17673	12	26	of	of	ADP
ajst-17673	12	27	which	which	PRON
ajst-17673	12	28	acute	acute	ADJ
ajst-17673	12	29	coronary	coronary	ADJ
ajst-17673	12	30	syndrome	syndrome	NOUN
ajst-17673	12	31	(	(	PUNCT
ajst-17673	12	32	acs	acs	PROPN
ajst-17673	12	33	)	)	PUNCT
ajst-17673	12	34	is	be	AUX
ajst-17673	12	35	a	a	DET
ajst-17673	12	36	group	group	NOUN
ajst-17673	12	37	of	of	ADP
ajst-17673	12	38	clinical	clinical	ADJ
ajst-17673	12	39	syndromes	syndrome	NOUN
ajst-17673	12	40	caused	cause	VERB
ajst-17673	12	41	by	by	ADP
ajst-17673	12	42	acute	acute	ADJ
ajst-17673	12	43	myocardial	myocardial	ADJ
ajst-17673	12	44	ischemia	ischemia	NOUN
ajst-17673	12	45	.	.	PUNCT
ajst-17673	13	1	standardized	standardized	ADJ
ajst-17673	13	2	management	management	NOUN
ajst-17673	13	3	of	of	ADP
ajst-17673	13	4	coronary	coronary	ADJ
ajst-17673	13	5	artery	artery	NOUN
ajst-17673	13	6	disease	disease	NOUN
ajst-17673	13	7	is	be	AUX
ajst-17673	13	8	the	the	DET
ajst-17673	13	9	key	key	NOUN
ajst-17673	13	10	to	to	ADP
ajst-17673	13	11	improving	improve	VERB
ajst-17673	13	12	prognosis	prognosis	NOUN
ajst-17673	13	13	and	and	CCONJ
ajst-17673	13	14	reducing	reduce	VERB
ajst-17673	13	15	mortality	mortality	NOUN
ajst-17673	13	16	,	,	PUNCT
ajst-17673	13	17	and	and	CCONJ
ajst-17673	13	18	antiplatelet	antiplatelet	NOUN
ajst-17673	13	19	therapy	therapy	NOUN
ajst-17673	13	20	is	be	AUX
ajst-17673	13	21	the	the	DET
ajst-17673	13	22	cornerstone	cornerstone	NOUN
ajst-17673	13	23	of	of	ADP
ajst-17673	13	24	coronary	coronary	ADJ
ajst-17673	13	25	artery	artery	NOUN
ajst-17673	13	26	disease	disease	NOUN
ajst-17673	13	27	management	management	NOUN
ajst-17673	13	28	,	,	PUNCT
ajst-17673	13	29	regardless	regardless	ADV
ajst-17673	13	30	of	of	ADP
ajst-17673	13	31	whether	whether	SCONJ
ajst-17673	13	32	drug	drug	NOUN
ajst-17673	13	33	or	or	CCONJ
ajst-17673	13	34	interventional	interventional	ADJ
ajst-17673	13	35	therapy	therapy	NOUN
ajst-17673	13	36	is	be	AUX
ajst-17673	13	37	adopted	adopt	VERB
ajst-17673	13	38	.	.	PUNCT
ajst-17673	14	1	percutaneous	percutaneous	ADJ
ajst-17673	14	2	coronary	coronary	ADJ
ajst-17673	14	3	intervention	intervention	NOUN
ajst-17673	14	4	(	(	PUNCT
ajst-17673	14	5	pci	pci	ADJ
ajst-17673	14	6	)	)	PUNCT
ajst-17673	14	7	is	be	AUX
ajst-17673	14	8	one	one	NUM
ajst-17673	14	9	of	of	ADP
ajst-17673	14	10	the	the	DET
ajst-17673	14	11	most	most	ADV
ajst-17673	14	12	widely	widely	ADV
ajst-17673	14	13	used	use	VERB
ajst-17673	14	14	procedures	procedure	NOUN
ajst-17673	14	15	in	in	ADP
ajst-17673	14	16	the	the	DET
ajst-17673	14	17	world	world	NOUN
ajst-17673	14	18	,	,	PUNCT
ajst-17673	14	19	and	and	CCONJ
ajst-17673	14	20	in	in	ADP
ajst-17673	14	21	addition	addition	NOUN
ajst-17673	14	22	to	to	ADP
ajst-17673	14	23	aspirin	aspirin	NOUN
ajst-17673	14	24	,	,	PUNCT
ajst-17673	14	25	the	the	DET
ajst-17673	14	26	introduction	introduction	NOUN
ajst-17673	14	27	of	of	ADP
ajst-17673	14	28	thienopyridine	thienopyridine	NOUN
ajst-17673	14	29	-	-	PUNCT
ajst-17673	14	30	type	type	NOUN
ajst-17673	14	31	p2y12	p2y12	NOUN
ajst-17673	14	32	receptor	receptor	NOUN
ajst-17673	14	33	inhibitors	inhibitor	NOUN
ajst-17673	14	34	,	,	PUNCT
ajst-17673	14	35	known	know	VERB
ajst-17673	14	36	as	as	ADP
ajst-17673	14	37	dual	dual	ADJ
ajst-17673	14	38	antiplatelet	antiplatelet	NOUN
ajst-17673	14	39	therapy	therapy	NOUN
ajst-17673	14	40	(	(	PUNCT
ajst-17673	14	41	dapt	dapt	NOUN
ajst-17673	14	42	)	)	PUNCT
ajst-17673	15	1	[	[	X
ajst-17673	15	2	1	1	NUM
ajst-17673	15	3	]	]	PUNCT
ajst-17673	15	4	,	,	PUNCT
ajst-17673	15	5	has	have	AUX
ajst-17673	15	6	led	lead	VERB
ajst-17673	15	7	to	to	ADP
ajst-17673	15	8	a	a	DET
ajst-17673	15	9	significant	significant	ADJ
ajst-17673	15	10	reduction	reduction	NOUN
ajst-17673	15	11	in	in	ADP
ajst-17673	15	12	the	the	DET
ajst-17673	15	13	number	number	NOUN
ajst-17673	15	14	of	of	ADP
ajst-17673	15	15	postprocedural	postprocedural	ADJ
ajst-17673	15	16	thrombotic	thrombotic	ADJ
ajst-17673	15	17	events	event	NOUN
ajst-17673	15	18	[	[	X
ajst-17673	15	19	2	2	NUM
ajst-17673	15	20	]	]	PUNCT
ajst-17673	15	21	.	.	PUNCT
ajst-17673	16	1	clopidogrel	clopidogrel	PROPN
ajst-17673	16	2	became	become	VERB
ajst-17673	16	3	the	the	DET
ajst-17673	16	4	first	first	ADJ
ajst-17673	16	5	widely	widely	ADV
ajst-17673	16	6	used	use	VERB
ajst-17673	16	7	p2y12	p2y12	NOUN
ajst-17673	16	8	inhibitor	inhibitor	NOUN
ajst-17673	16	9	to	to	PART
ajst-17673	16	10	reduce	reduce	VERB
ajst-17673	16	11	the	the	DET
ajst-17673	16	12	risk	risk	NOUN
ajst-17673	16	13	of	of	ADP
ajst-17673	16	14	thrombotic	thrombotic	ADJ
ajst-17673	16	15	complications	complication	NOUN
ajst-17673	16	16	after	after	ADP
ajst-17673	16	17	pci	pci	ADJ
ajst-17673	16	18	with	with	ADP
ajst-17673	16	19	an	an	DET
ajst-17673	16	20	acceptable	acceptable	ADJ
ajst-17673	16	21	safety	safety	NOUN
ajst-17673	16	22	profile	profile	NOUN
ajst-17673	16	23	.	.	PUNCT
ajst-17673	17	1	however	however	ADV
ajst-17673	17	2	,	,	PUNCT
ajst-17673	17	3	the	the	DET
ajst-17673	17	4	active	active	ADJ
ajst-17673	17	5	metabolite	metabolite	NOUN
ajst-17673	17	6	production	production	NOUN
ajst-17673	17	7	of	of	ADP
ajst-17673	17	8	clopidogrel	clopidogrel	NOUN
ajst-17673	17	9	is	be	AUX
ajst-17673	17	10	unpredictable	unpredictable	ADJ
ajst-17673	17	11	,	,	PUNCT
ajst-17673	17	12	leading	lead	VERB
ajst-17673	17	13	to	to	ADP
ajst-17673	17	14	significant	significant	ADJ
ajst-17673	17	15	inter	inter	ADJ
ajst-17673	17	16	-	-	ADJ
ajst-17673	17	17	patient	patient	ADJ
ajst-17673	17	18	differences	difference	NOUN
ajst-17673	17	19	in	in	ADP
ajst-17673	17	20	the	the	DET
ajst-17673	17	21	level	level	NOUN
ajst-17673	17	22	of	of	ADP
ajst-17673	17	23	platelet	platelet	NOUN
ajst-17673	17	24	response	response	NOUN
ajst-17673	17	25	during	during	ADP
ajst-17673	17	26	treatment	treatment	NOUN
ajst-17673	17	27	[	[	X
ajst-17673	17	28	3	3	NUM
ajst-17673	17	29	]	]	PUNCT
ajst-17673	17	30	.	.	PUNCT
ajst-17673	18	1	cyp2c19	cyp2c19	NOUN
ajst-17673	18	2	gene	gene	NOUN
ajst-17673	18	3	polymorphisms	polymorphism	NOUN
ajst-17673	18	4	have	have	AUX
ajst-17673	18	5	been	be	AUX
ajst-17673	18	6	identified	identify	VERB
ajst-17673	18	7	as	as	ADP
ajst-17673	18	8	contributing	contribute	VERB
ajst-17673	18	9	,	,	PUNCT
ajst-17673	18	10	at	at	ADP
ajst-17673	18	11	least	least	ADJ
ajst-17673	18	12	in	in	ADP
ajst-17673	18	13	part	part	NOUN
ajst-17673	18	14	,	,	PUNCT
ajst-17673	18	15	to	to	ADP
ajst-17673	18	16	the	the	DET
ajst-17673	18	17	observed	observe	VERB
ajst-17673	18	18	differences	difference	NOUN
ajst-17673	18	19	in	in	ADP
ajst-17673	18	20	clopidogrel	clopidogrel	NOUN
ajst-17673	18	21	response	response	NOUN
ajst-17673	18	22	[	[	X
ajst-17673	18	23	4	4	X
ajst-17673	18	24	]	]	X
ajst-17673	19	1	[	[	X
ajst-17673	19	2	5	5	NUM
ajst-17673	19	3	]	]	X
ajst-17673	19	4	[	[	X
ajst-17673	19	5	6	6	NUM
ajst-17673	19	6	]	]	X
ajst-17673	19	7	[	[	X
ajst-17673	19	8	7	7	NUM
ajst-17673	19	9	]	]	PUNCT
ajst-17673	19	10	.	.	PUNCT
ajst-17673	20	1	however	however	ADV
ajst-17673	20	2	,	,	PUNCT
ajst-17673	20	3	this	this	DET
ajst-17673	20	4	difference	difference	NOUN
ajst-17673	20	5	is	be	AUX
ajst-17673	20	6	ten	ten	NUM
ajst-17673	20	7	dangerous	dangerous	ADJ
ajst-17673	20	8	for	for	ADP
ajst-17673	20	9	the	the	DET
ajst-17673	20	10	individual	individual	ADJ
ajst-17673	20	11	patient	patient	NOUN
ajst-17673	20	12	,	,	PUNCT
ajst-17673	20	13	doubling	double	VERB
ajst-17673	20	14	the	the	DET
ajst-17673	20	15	risk	risk	NOUN
ajst-17673	20	16	of	of	ADP
ajst-17673	20	17	bleeding	bleed	VERB
ajst-17673	20	18	despite	despite	SCONJ
ajst-17673	20	19	the	the	DET
ajst-17673	20	20	fact	fact	NOUN
ajst-17673	20	21	that	that	SCONJ
ajst-17673	20	22	tegretol	tegretol	NOUN
ajst-17673	20	23	has	have	AUX
ajst-17673	20	24	greater	great	ADJ
ajst-17673	20	25	watchfulness	watchfulness	NOUN
ajst-17673	20	26	and	and	CCONJ
ajst-17673	20	27	does	do	AUX
ajst-17673	20	28	not	not	PART
ajst-17673	20	29	require	require	VERB
ajst-17673	20	30	cyp2c19	cyp2c19	NOUN
ajst-17673	20	31	gene	gene	NOUN
ajst-17673	20	32	metabolism	metabolism	NOUN
ajst-17673	20	33	[	[	X
ajst-17673	20	34	8	8	X
ajst-17673	20	35	]	]	X
ajst-17673	21	1	[	[	X
ajst-17673	21	2	9	9	NUM
ajst-17673	21	3	]	]	PUNCT
ajst-17673	21	4	.	.	PUNCT
ajst-17673	22	1	coronary	coronary	ADJ
ajst-17673	22	2	heart	heart	NOUN
ajst-17673	22	3	disease	disease	NOUN
ajst-17673	22	4	with	with	ADP
ajst-17673	22	5	the	the	DET
ajst-17673	22	6	age	age	NOUN
ajst-17673	22	7	of	of	ADP
ajst-17673	22	8	morbidity	morbidity	NOUN
ajst-17673	22	9	and	and	CCONJ
ajst-17673	22	10	mortality	mortality	NOUN
ajst-17673	22	11	gradually	gradually	ADV
ajst-17673	22	12	increased	increase	VERB
ajst-17673	22	13	,	,	PUNCT
ajst-17673	22	14	while	while	SCONJ
ajst-17673	22	15	the	the	DET
ajst-17673	22	16	elderly	elderly	ADJ
ajst-17673	22	17	coronary	coronary	ADJ
ajst-17673	22	18	artery	artery	NOUN
ajst-17673	22	19	lesions	lesion	NOUN
ajst-17673	22	20	are	be	AUX
ajst-17673	22	21	more	more	ADV
ajst-17673	22	22	complex	complex	ADJ
ajst-17673	22	23	,	,	PUNCT
ajst-17673	22	24	such	such	ADJ
ajst-17673	22	25	studies	study	NOUN
ajst-17673	22	26	are	be	AUX
ajst-17673	22	27	less	less	ADJ
ajst-17673	22	28	in	in	ADP
ajst-17673	22	29	our	our	PRON
ajst-17673	22	30	country	country	NOUN
ajst-17673	22	31	,	,	PUNCT
ajst-17673	22	32	so	so	SCONJ
ajst-17673	22	33	it	it	PRON
ajst-17673	22	34	is	be	AUX
ajst-17673	22	35	crucial	crucial	ADJ
ajst-17673	22	36	to	to	PART
ajst-17673	22	37	explore	explore	VERB
ajst-17673	22	38	more	more	ADV
ajst-17673	22	39	personalized	personalized	ADJ
ajst-17673	22	40	and	and	CCONJ
ajst-17673	22	41	scientific	scientific	ADJ
ajst-17673	22	42	anti	anti	ADJ
ajst-17673	22	43	-	-	ADJ
ajst-17673	22	44	plate	plate	ADJ
ajst-17673	22	45	program	program	NOUN
ajst-17673	22	46	.	.	PUNCT
ajst-17673	23	1	2	2	X
ajst-17673	23	2	.	.	X
ajst-17673	23	3	data	datum	NOUN
ajst-17673	23	4	and	and	CCONJ
ajst-17673	23	5	methods	method	NOUN
ajst-17673	23	6	2.1	2.1	NUM
ajst-17673	23	7	.	.	PUNCT
ajst-17673	24	1	study	study	NOUN
ajst-17673	24	2	population	population	NOUN
ajst-17673	24	3	acs	acs	PROPN
ajst-17673	24	4	patients	patient	NOUN
ajst-17673	24	5	(	(	PUNCT
ajst-17673	24	6	aged	aged	ADJ
ajst-17673	24	7	≥65	≥65	NUM
ajst-17673	24	8	years	year	NOUN
ajst-17673	24	9	)	)	PUNCT
ajst-17673	24	10	who	who	PRON
ajst-17673	24	11	were	be	AUX
ajst-17673	24	12	admitted	admit	VERB
ajst-17673	24	13	to	to	ADP
ajst-17673	24	14	the	the	DET
ajst-17673	24	15	department	department	NOUN
ajst-17673	24	16	of	of	ADP
ajst-17673	24	17	cardiovascular	cardiovascular	ADJ
ajst-17673	24	18	medicine	medicine	NOUN
ajst-17673	24	19	of	of	ADP
ajst-17673	24	20	huaqiao	huaqiao	NOUN
ajst-17673	24	21	hospital	hospital	NOUN
ajst-17673	24	22	from	from	ADP
ajst-17673	24	23	2014	2014	NUM
ajst-17673	24	24	to	to	ADP
ajst-17673	24	25	2020	2020	NUM
ajst-17673	24	26	were	be	AUX
ajst-17673	24	27	divided	divide	VERB
ajst-17673	24	28	into	into	ADP
ajst-17673	24	29	the	the	DET
ajst-17673	24	30	clopidogrel	clopidogrel	NOUN
ajst-17673	24	31	group	group	NOUN
ajst-17673	24	32	and	and	CCONJ
ajst-17673	24	33	the	the	DET
ajst-17673	24	34	tegretol	tegretol	PROPN
ajst-17673	24	35	group	group	NOUN
ajst-17673	24	36	according	accord	VERB
ajst-17673	24	37	to	to	ADP
ajst-17673	24	38	the	the	DET
ajst-17673	24	39	type	type	NOUN
ajst-17673	24	40	of	of	ADP
ajst-17673	24	41	p2y12	p2y12	NOUN
ajst-17673	24	42	receptor	receptor	NOUN
ajst-17673	24	43	inhibitor	inhibitor	NOUN
ajst-17673	24	44	they	they	PRON
ajst-17673	24	45	were	be	AUX
ajst-17673	24	46	taking	take	VERB
ajst-17673	24	47	at	at	ADP
ajst-17673	24	48	discharge	discharge	NOUN
ajst-17673	24	49	,	,	PUNCT
ajst-17673	24	50	with	with	ADP
ajst-17673	24	51	165	165	NUM
ajst-17673	24	52	patients	patient	NOUN
ajst-17673	24	53	in	in	ADP
ajst-17673	24	54	the	the	DET
ajst-17673	24	55	tegretol	tegretol	PROPN
ajst-17673	24	56	group	group	NOUN
ajst-17673	24	57	,	,	PUNCT
ajst-17673	24	58	aged	aged	ADJ
ajst-17673	24	59	73.6±6.4	73.6±6.4	NUM
ajst-17673	24	60	years	year	NOUN
ajst-17673	24	61	,	,	PUNCT
ajst-17673	24	62	and	and	CCONJ
ajst-17673	24	63	59	59	NUM
ajst-17673	24	64	women	woman	NOUN
ajst-17673	24	65	(	(	PUNCT
ajst-17673	24	66	36.2	36.2	NUM
ajst-17673	24	67	%	%	NOUN
ajst-17673	24	68	)	)	PUNCT
ajst-17673	24	69	,	,	PUNCT
ajst-17673	24	70	and	and	CCONJ
ajst-17673	24	71	320	320	NUM
ajst-17673	24	72	patients	patient	NOUN
ajst-17673	24	73	in	in	ADP
ajst-17673	24	74	the	the	DET
ajst-17673	24	75	clopidogrel	clopidogrel	NOUN
ajst-17673	24	76	group	group	NOUN
ajst-17673	24	77	,	,	PUNCT
ajst-17673	24	78	aged	aged	ADJ
ajst-17673	24	79	74.9±6.3	74.9±6.3	NUM
ajst-17673	24	80	years	year	NOUN
ajst-17673	24	81	,	,	PUNCT
ajst-17673	24	82	and	and	CCONJ
ajst-17673	24	83	144	144	NUM
ajst-17673	24	84	women	woman	NOUN
ajst-17673	24	85	(	(	PUNCT
ajst-17673	24	86	44.2	44.2	NUM
ajst-17673	24	87	%	%	NOUN
ajst-17673	24	88	)	)	PUNCT
ajst-17673	24	89	.	.	PUNCT
ajst-17673	25	1	6.3	6.3	NUM
ajst-17673	25	2	years	year	NOUN
ajst-17673	25	3	,	,	PUNCT
ajst-17673	25	4	144	144	NUM
ajst-17673	25	5	(	(	PUNCT
ajst-17673	25	6	44.2	44.2	NUM
ajst-17673	25	7	%	%	NOUN
ajst-17673	25	8	)	)	PUNCT
ajst-17673	25	9	females	female	NOUN
ajst-17673	25	10	.	.	PUNCT
ajst-17673	26	1	patients	patient	NOUN
ajst-17673	26	2	with	with	ADP
ajst-17673	26	3	the	the	DET
ajst-17673	26	4	following	follow	VERB
ajst-17673	26	5	conditions	condition	NOUN
ajst-17673	26	6	were	be	AUX
ajst-17673	26	7	also	also	ADV
ajst-17673	26	8	excluded	exclude	VERB
ajst-17673	26	9	:	:	PUNCT
ajst-17673	26	10	1	1	X
ajst-17673	26	11	)	)	PUNCT
ajst-17673	26	12	combined	combined	ADJ
ajst-17673	26	13	coagulation	coagulation	NOUN
ajst-17673	26	14	dysfunctional	dysfunctional	ADJ
ajst-17673	26	15	diseases	disease	NOUN
ajst-17673	26	16	(	(	PUNCT
ajst-17673	26	17	such	such	ADJ
ajst-17673	26	18	as	as	ADP
ajst-17673	26	19	nephrotic	nephrotic	ADJ
ajst-17673	26	20	syndrome	syndrome	NOUN
ajst-17673	26	21	,	,	PUNCT
ajst-17673	26	22	tumor	tumor	NOUN
ajst-17673	26	23	,	,	PUNCT
ajst-17673	26	24	autoimmune	autoimmune	ADJ
ajst-17673	26	25	diseases	disease	NOUN
ajst-17673	26	26	,	,	PUNCT
ajst-17673	26	27	hematologic	hematologic	NOUN
ajst-17673	26	28	diseases	disease	NOUN
ajst-17673	26	29	,	,	PUNCT
ajst-17673	26	30	etc	etc	X
ajst-17673	26	31	.	.	X
ajst-17673	26	32	)	)	PUNCT
ajst-17673	26	33	and	and	CCONJ
ajst-17673	26	34	those	those	PRON
ajst-17673	26	35	who	who	PRON
ajst-17673	26	36	were	be	AUX
ajst-17673	26	37	bedridden	bedridden	ADJ
ajst-17673	26	38	for	for	ADP
ajst-17673	26	39	a	a	DET
ajst-17673	26	40	long	long	ADJ
ajst-17673	26	41	time	time	NOUN
ajst-17673	26	42	;	;	PUNCT
ajst-17673	26	43	2	2	X
ajst-17673	26	44	)	)	PUNCT
ajst-17673	26	45	patients	patient	NOUN
ajst-17673	26	46	with	with	ADP
ajst-17673	26	47	severe	severe	ADJ
ajst-17673	26	48	renal	renal	ADJ
ajst-17673	26	49	insufficiency	insufficiency	NOUN
ajst-17673	26	50	,	,	PUNCT
ajst-17673	26	51	hepatic	hepatic	ADJ
ajst-17673	26	52	insufficiency	insufficiency	NOUN
ajst-17673	26	53	,	,	PUNCT
ajst-17673	26	54	abnormal	abnormal	ADJ
ajst-17673	26	55	thyroid	thyroid	NOUN
ajst-17673	26	56	function	function	NOUN
ajst-17673	26	57	;	;	PUNCT
ajst-17673	26	58	(	(	PUNCT
ajst-17673	26	59	3	3	X
ajst-17673	26	60	)	)	PUNCT
ajst-17673	26	61	patients	patient	NOUN
ajst-17673	26	62	with	with	ADP
ajst-17673	26	63	newly	newly	ADV
ajst-17673	26	64	occurring	occur	VERB
ajst-17673	26	65	gastrointestinal	gastrointestinal	ADJ
ajst-17673	26	66	bleeding	bleeding	NOUN
ajst-17673	26	67	or	or	CCONJ
ajst-17673	26	68	bleeding	bleed	VERB
ajst-17673	26	69	from	from	ADP
ajst-17673	26	70	oral	oral	ADJ
ajst-17673	26	71	antiplate	antiplate	NOUN
ajst-17673	26	72	drugs	drug	NOUN
ajst-17673	26	73	.	.	PUNCT
ajst-17673	27	1	4	4	X
ajst-17673	27	2	)	)	PUNCT
ajst-17673	27	3	patients	patient	NOUN
ajst-17673	27	4	with	with	ADP
ajst-17673	27	5	incomplete	incomplete	ADJ
ajst-17673	27	6	medical	medical	ADJ
ajst-17673	27	7	record	record	NOUN
ajst-17673	27	8	data	datum	NOUN
ajst-17673	27	9	.	.	PUNCT
ajst-17673	28	1	5	5	X
ajst-17673	28	2	)	)	PUNCT
ajst-17673	28	3	patients	patient	NOUN
ajst-17673	28	4	with	with	ADP
ajst-17673	28	5	new	new	ADJ
ajst-17673	28	6	tumor	tumor	NOUN
ajst-17673	28	7	survival	survival	NOUN
ajst-17673	28	8	less	less	ADJ
ajst-17673	28	9	than	than	ADP
ajst-17673	28	10	1	1	NUM
ajst-17673	28	11	year	year	NOUN
ajst-17673	28	12	after	after	ADP
ajst-17673	28	13	discharge	discharge	NOUN
ajst-17673	28	14	.	.	PUNCT
ajst-17673	29	1	6	6	NUM
ajst-17673	29	2	)	)	PUNCT
ajst-17673	29	3	patients	patient	NOUN
ajst-17673	29	4	who	who	PRON
ajst-17673	29	5	change	change	VERB
ajst-17673	29	6	and	and	CCONJ
ajst-17673	29	7	stop	stop	VERB
ajst-17673	29	8	medication	medication	NOUN
ajst-17673	29	9	on	on	ADP
ajst-17673	29	10	their	their	PRON
ajst-17673	29	11	own	own	ADJ
ajst-17673	29	12	,	,	PUNCT
ajst-17673	29	13	as	as	ADV
ajst-17673	29	14	well	well	ADV
ajst-17673	29	15	as	as	ADP
ajst-17673	29	16	patients	patient	NOUN
ajst-17673	29	17	who	who	PRON
ajst-17673	29	18	fail	fail	VERB
ajst-17673	29	19	to	to	PART
ajst-17673	29	20	visit	visit	VERB
ajst-17673	29	21	or	or	CCONJ
ajst-17673	29	22	follow	follow	VERB
ajst-17673	29	23	up	up	ADP
ajst-17673	29	24	.	.	PUNCT
ajst-17673	30	1	2.2	2.2	NUM
ajst-17673	30	2	.	.	PUNCT
ajst-17673	31	1	research	research	NOUN
ajst-17673	31	2	methodology	methodology	NOUN
ajst-17673	31	3	a	a	DET
ajst-17673	31	4	retrospective	retrospective	ADJ
ajst-17673	31	5	cohort	cohort	NOUN
ajst-17673	31	6	study	study	NOUN
ajst-17673	31	7	research	research	NOUN
ajst-17673	31	8	method	method	NOUN
ajst-17673	31	9	was	be	AUX
ajst-17673	31	10	used	use	VERB
ajst-17673	31	11	,	,	PUNCT
ajst-17673	31	12	and	and	CCONJ
ajst-17673	31	13	the	the	DET
ajst-17673	31	14	admission	admission	NOUN
ajst-17673	31	15	medical	medical	ADJ
ajst-17673	31	16	records	record	NOUN
ajst-17673	31	17	of	of	ADP
ajst-17673	31	18	patients	patient	NOUN
ajst-17673	31	19	who	who	PRON
ajst-17673	31	20	met	meet	VERB
ajst-17673	31	21	the	the	DET
ajst-17673	31	22	study	study	NOUN
ajst-17673	31	23	criteria	criterion	NOUN
ajst-17673	31	24	were	be	AUX
ajst-17673	31	25	used	use	VERB
ajst-17673	31	26	as	as	ADP
ajst-17673	31	27	the	the	DET
ajst-17673	31	28	baseline	baseline	NOUN
ajst-17673	31	29	for	for	ADP
ajst-17673	31	30	this	this	DET
ajst-17673	31	31	study	study	NOUN
ajst-17673	31	32	.	.	PUNCT
ajst-17673	32	1	information	information	NOUN
ajst-17673	32	2	on	on	ADP
ajst-17673	32	3	patients	patient	NOUN
ajst-17673	32	4	'	'	PART
ajst-17673	32	5	gender	gender	NOUN
ajst-17673	32	6	,	,	PUNCT
ajst-17673	32	7	age	age	NOUN
ajst-17673	32	8	,	,	PUNCT
ajst-17673	32	9	admission	admission	NOUN
ajst-17673	32	10	time	time	NOUN
ajst-17673	32	11	,	,	PUNCT
ajst-17673	32	12	discharge	discharge	VERB
ajst-17673	32	13	diagnosis	diagnosis	NOUN
ajst-17673	32	14	,	,	PUNCT
ajst-17673	32	15	discharge	discharge	VERB
ajst-17673	32	16	with	with	ADP
ajst-17673	32	17	medication	medication	NOUN
ajst-17673	32	18	,	,	PUNCT
ajst-17673	32	19	and	and	CCONJ
ajst-17673	32	20	vascular	vascular	ADJ
ajst-17673	32	21	95	95	NUM
ajst-17673	32	22	risk	risk	NOUN
ajst-17673	32	23	factors	factor	NOUN
ajst-17673	32	24	(	(	PUNCT
ajst-17673	32	25	smoking	smoking	NOUN
ajst-17673	32	26	,	,	PUNCT
ajst-17673	32	27	hypertension	hypertension	NOUN
ajst-17673	32	28	,	,	PUNCT
ajst-17673	32	29	diabetes	diabetes	NOUN
ajst-17673	32	30	mellitus	mellitus	NOUN
ajst-17673	32	31	,	,	PUNCT
ajst-17673	32	32	hyperlipidemia	hyperlipidemia	NOUN
ajst-17673	32	33	)	)	PUNCT
ajst-17673	32	34	were	be	AUX
ajst-17673	32	35	collected	collect	VERB
ajst-17673	32	36	.	.	PUNCT
ajst-17673	33	1	patients	patient	NOUN
ajst-17673	33	2	'	'	PART
ajst-17673	33	3	concomitant	concomitant	ADJ
ajst-17673	33	4	diseases	disease	NOUN
ajst-17673	33	5	were	be	AUX
ajst-17673	33	6	obtained	obtain	VERB
ajst-17673	33	7	from	from	ADP
ajst-17673	33	8	past	past	ADJ
ajst-17673	33	9	history	history	NOUN
ajst-17673	33	10	,	,	PUNCT
ajst-17673	33	11	medication	medication	NOUN
ajst-17673	33	12	use	use	NOUN
ajst-17673	33	13	and	and	CCONJ
ajst-17673	33	14	secondary	secondary	ADJ
ajst-17673	33	15	diagnoses	diagnosis	NOUN
ajst-17673	33	16	.	.	PUNCT
ajst-17673	34	1	patients	patient	NOUN
ajst-17673	34	2	were	be	AUX
ajst-17673	34	3	categorized	categorize	VERB
ajst-17673	34	4	into	into	ADP
ajst-17673	34	5	clopidogrel	clopidogrel	NOUN
ajst-17673	34	6	and	and	CCONJ
ajst-17673	34	7	tegretol	tegretol	NOUN
ajst-17673	34	8	groups	group	NOUN
ajst-17673	34	9	based	base	VERB
ajst-17673	34	10	on	on	ADP
ajst-17673	34	11	their	their	PRON
ajst-17673	34	12	discharge	discharge	NOUN
ajst-17673	34	13	carryover	carryover	NOUN
ajst-17673	34	14	medications	medication	NOUN
ajst-17673	34	15	.	.	PUNCT
ajst-17673	35	1	patients	patient	NOUN
ajst-17673	35	2	were	be	AUX
ajst-17673	35	3	counted	count	VERB
ajst-17673	35	4	based	base	VERB
ajst-17673	35	5	on	on	ADP
ajst-17673	35	6	outpatient	outpatient	NOUN
ajst-17673	35	7	visits	visit	NOUN
ajst-17673	35	8	,	,	PUNCT
ajst-17673	35	9	telephone	telephone	NOUN
ajst-17673	35	10	follow	follow	NOUN
ajst-17673	35	11	-	-	PUNCT
ajst-17673	35	12	up	up	NOUN
ajst-17673	35	13	,	,	PUNCT
ajst-17673	35	14	or	or	CCONJ
ajst-17673	35	15	hospitalization	hospitalization	NOUN
ajst-17673	35	16	.	.	PUNCT
ajst-17673	36	1	the	the	DET
ajst-17673	36	2	end	end	NOUN
ajst-17673	36	3	point	point	NOUN
ajst-17673	36	4	was	be	AUX
ajst-17673	36	5	a	a	DET
ajst-17673	36	6	composite	composite	ADJ
ajst-17673	36	7	end	end	NOUN
ajst-17673	36	8	point	point	NOUN
ajst-17673	36	9	of	of	ADP
ajst-17673	36	10	1	1	NUM
ajst-17673	36	11	-	-	PUNCT
ajst-17673	36	12	year	year	NOUN
ajst-17673	36	13	post	post	ADJ
ajst-17673	36	14	-	-	ADJ
ajst-17673	36	15	discharge	discharge	ADJ
ajst-17673	36	16	stroke	stroke	NOUN
ajst-17673	36	17	events	event	NOUN
ajst-17673	36	18	in	in	ADP
ajst-17673	36	19	the	the	DET
ajst-17673	36	20	absence	absence	NOUN
ajst-17673	36	21	of	of	ADP
ajst-17673	36	22	stenosis	stenosis	NOUN
ajst-17673	36	23	,	,	PUNCT
ajst-17673	36	24	i.e.	i.e.	X
ajst-17673	36	25	,	,	PUNCT
ajst-17673	36	26	a	a	DET
ajst-17673	36	27	composite	composite	ADJ
ajst-17673	36	28	end	end	NOUN
ajst-17673	36	29	point	point	NOUN
ajst-17673	36	30	that	that	PRON
ajst-17673	36	31	included	include	VERB
ajst-17673	36	32	cardiac	cardiac	ADJ
ajst-17673	36	33	death	death	NOUN
ajst-17673	36	34	,	,	PUNCT
ajst-17673	36	35	cardiac	cardiac	ADJ
ajst-17673	36	36	infarction	infarction	NOUN
ajst-17673	36	37	,	,	PUNCT
ajst-17673	36	38	or	or	CCONJ
ajst-17673	36	39	stroke	stroke	NOUN
ajst-17673	36	40	in	in	ADP
ajst-17673	36	41	the	the	DET
ajst-17673	36	42	absence	absence	NOUN
ajst-17673	36	43	of	of	ADP
ajst-17673	36	44	stenosis	stenosis	NOUN
ajst-17673	36	45	.	.	PUNCT
ajst-17673	37	1	secondary	secondary	ADJ
ajst-17673	37	2	endpoints	endpoint	NOUN
ajst-17673	37	3	were	be	AUX
ajst-17673	37	4	unstable	unstable	ADJ
ajst-17673	37	5	angina	angina	NOUN
ajst-17673	37	6	,	,	PUNCT
ajst-17673	37	7	in	in	ADP
ajst-17673	37	8	-	-	PUNCT
ajst-17673	37	9	stent	stent	NOUN
ajst-17673	37	10	stenosis	stenosis	NOUN
ajst-17673	37	11	,	,	PUNCT
ajst-17673	37	12	target	target	NOUN
ajst-17673	37	13	vessel	vessel	NOUN
ajst-17673	37	14	revascularization	revascularization	NOUN
ajst-17673	37	15	,	,	PUNCT
ajst-17673	37	16	allcause	allcause	ADP
ajst-17673	37	17	mortality	mortality	NOUN
ajst-17673	37	18	,	,	PUNCT
ajst-17673	37	19	and	and	CCONJ
ajst-17673	37	20	barc	barc	PROPN
ajst-17673	37	21	type	type	NOUN
ajst-17673	37	22	2	2	NUM
ajst-17673	37	23	,	,	PUNCT
ajst-17673	37	24	3	3	NUM
ajst-17673	37	25	,	,	PUNCT
ajst-17673	37	26	and	and	CCONJ
ajst-17673	37	27	5	5	NUM
ajst-17673	37	28	events	event	NOUN
ajst-17673	37	29	as	as	SCONJ
ajst-17673	37	30	defined	define	VERB
ajst-17673	37	31	by	by	ADP
ajst-17673	37	32	the	the	DET
ajst-17673	37	33	barc	barc	PROPN
ajst-17673	37	34	academic	academic	PROPN
ajst-17673	37	35	research	research	PROPN
ajst-17673	37	36	consortium	consortium	PROPN
ajst-17673	37	37	(	(	PUNCT
ajst-17673	37	38	barc	barc	PROPN
ajst-17673	37	39	)	)	PUNCT
ajst-17673	37	40	at	at	ADP
ajst-17673	37	41	1	1	NUM
ajst-17673	37	42	year	year	NOUN
ajst-17673	37	43	.	.	PUNCT
ajst-17673	38	1	2.3	2.3	NUM
ajst-17673	38	2	.	.	PUNCT
ajst-17673	39	1	statistical	statistical	ADJ
ajst-17673	39	2	analysis	analysis	NOUN
ajst-17673	39	3	spss	spss	X
ajst-17673	39	4	25.0	25.0	NUM
ajst-17673	39	5	software	software	NOUN
ajst-17673	39	6	was	be	AUX
ajst-17673	39	7	used	use	VERB
ajst-17673	39	8	to	to	PART
ajst-17673	39	9	analyze	analyze	VERB
ajst-17673	39	10	the	the	DET
ajst-17673	39	11	data	datum	NOUN
ajst-17673	39	12	,	,	PUNCT
ajst-17673	39	13	the	the	DET
ajst-17673	39	14	count	count	NOUN
ajst-17673	39	15	data	datum	NOUN
ajst-17673	39	16	were	be	AUX
ajst-17673	39	17	expressed	express	VERB
ajst-17673	39	18	as	as	ADP
ajst-17673	39	19	the	the	DET
ajst-17673	39	20	number	number	NOUN
ajst-17673	39	21	of	of	ADP
ajst-17673	39	22	cases	case	NOUN
ajst-17673	39	23	and	and	CCONJ
ajst-17673	39	24	percentage	percentage	NOUN
ajst-17673	39	25	,	,	PUNCT
ajst-17673	39	26	the	the	DET
ajst-17673	39	27	comparison	comparison	NOUN
ajst-17673	39	28	between	between	ADP
ajst-17673	39	29	groups	group	NOUN
ajst-17673	39	30	was	be	AUX
ajst-17673	39	31	performed	perform	VERB
ajst-17673	39	32	by	by	ADP
ajst-17673	39	33	chi	chi	ADJ
ajst-17673	39	34	-	-	PUNCT
ajst-17673	39	35	square	square	ADJ
ajst-17673	39	36	test	test	NOUN
ajst-17673	39	37	,	,	PUNCT
ajst-17673	39	38	the	the	DET
ajst-17673	39	39	measurement	measurement	NOUN
ajst-17673	39	40	data	datum	NOUN
ajst-17673	39	41	were	be	AUX
ajst-17673	39	42	expressed	express	VERB
ajst-17673	39	43	as	as	ADP
ajst-17673	39	44	mean±standard	mean±standard	NOUN
ajst-17673	39	45	deviation	deviation	NOUN
ajst-17673	39	46	,	,	PUNCT
ajst-17673	39	47	the	the	DET
ajst-17673	39	48	comparison	comparison	NOUN
ajst-17673	39	49	between	between	ADP
ajst-17673	39	50	groups	group	NOUN
ajst-17673	39	51	was	be	AUX
ajst-17673	39	52	performed	perform	VERB
ajst-17673	39	53	by	by	ADP
ajst-17673	39	54	anova	anova	PROPN
ajst-17673	39	55	if	if	SCONJ
ajst-17673	39	56	it	it	PRON
ajst-17673	39	57	conformed	conform	VERB
ajst-17673	39	58	to	to	ADP
ajst-17673	39	59	normal	normal	ADJ
ajst-17673	39	60	distribution	distribution	NOUN
ajst-17673	39	61	,	,	PUNCT
ajst-17673	39	62	and	and	CCONJ
ajst-17673	39	63	the	the	DET
ajst-17673	39	64	comparison	comparison	NOUN
ajst-17673	39	65	between	between	ADP
ajst-17673	39	66	groups	group	NOUN
ajst-17673	39	67	was	be	AUX
ajst-17673	39	68	performed	perform	VERB
ajst-17673	39	69	by	by	ADP
ajst-17673	39	70	rank	rank	NOUN
ajst-17673	39	71	-	-	PUNCT
ajst-17673	39	72	sum	sum	NOUN
ajst-17673	39	73	test	test	NOUN
ajst-17673	39	74	if	if	SCONJ
ajst-17673	39	75	it	it	PRON
ajst-17673	39	76	did	do	AUX
ajst-17673	39	77	not	not	PART
ajst-17673	39	78	conform	conform	VERB
ajst-17673	39	79	to	to	ADP
ajst-17673	39	80	normal	normal	ADJ
ajst-17673	39	81	distribution	distribution	NOUN
ajst-17673	39	82	.	.	PUNCT
ajst-17673	40	1	p<0.05	p<0.05	NOUN
ajst-17673	40	2	indicated	indicate	VERB
ajst-17673	40	3	that	that	SCONJ
ajst-17673	40	4	the	the	DET
ajst-17673	40	5	difference	difference	NOUN
ajst-17673	40	6	was	be	AUX
ajst-17673	40	7	statistically	statistically	ADV
ajst-17673	40	8	significant	significant	ADJ
ajst-17673	40	9	.	.	PUNCT
ajst-17673	41	1	3	3	X
ajst-17673	41	2	.	.	NOUN
ajst-17673	41	3	results	result	VERB
ajst-17673	41	4	3.1	3.1	NUM
ajst-17673	41	5	comparison	comparison	NOUN
ajst-17673	41	6	of	of	ADP
ajst-17673	41	7	baseline	baseline	ADJ
ajst-17673	41	8	data	datum	NOUN
ajst-17673	41	9	between	between	ADP
ajst-17673	41	10	the	the	DET
ajst-17673	41	11	two	two	NUM
ajst-17673	41	12	groups	group	NOUN
ajst-17673	41	13	,	,	PUNCT
ajst-17673	41	14	out	out	ADP
ajst-17673	41	15	of	of	ADP
ajst-17673	41	16	385	385	NUM
ajst-17673	41	17	patients	patient	NOUN
ajst-17673	41	18	,	,	PUNCT
ajst-17673	41	19	320	320	NUM
ajst-17673	41	20	were	be	AUX
ajst-17673	41	21	treated	treat	VERB
ajst-17673	41	22	with	with	ADP
ajst-17673	41	23	clopidogrel	clopidogrel	NOUN
ajst-17673	41	24	and	and	CCONJ
ajst-17673	41	25	165	165	NUM
ajst-17673	41	26	patients	patient	NOUN
ajst-17673	41	27	were	be	AUX
ajst-17673	41	28	treated	treat	VERB
ajst-17673	41	29	with	with	ADP
ajst-17673	41	30	tegretol	tegretol	NOUN
ajst-17673	41	31	.	.	PUNCT
ajst-17673	42	1	there	there	PRON
ajst-17673	42	2	was	be	VERB
ajst-17673	42	3	a	a	DET
ajst-17673	42	4	difference	difference	NOUN
ajst-17673	42	5	in	in	ADP
ajst-17673	42	6	the	the	DET
ajst-17673	42	7	age	age	NOUN
ajst-17673	42	8	of	of	ADP
ajst-17673	42	9	the	the	DET
ajst-17673	42	10	patients	patient	NOUN
ajst-17673	42	11	in	in	ADP
ajst-17673	42	12	the	the	DET
ajst-17673	42	13	two	two	NUM
ajst-17673	42	14	groups	group	NOUN
ajst-17673	42	15	,	,	PUNCT
ajst-17673	42	16	and	and	CCONJ
ajst-17673	42	17	the	the	DET
ajst-17673	42	18	average	average	ADJ
ajst-17673	42	19	age	age	NOUN
ajst-17673	42	20	of	of	ADP
ajst-17673	42	21	patients	patient	NOUN
ajst-17673	42	22	using	use	VERB
ajst-17673	42	23	tegretol	tegretol	NOUN
ajst-17673	42	24	was	be	AUX
ajst-17673	42	25	lower	low	ADJ
ajst-17673	42	26	than	than	ADP
ajst-17673	42	27	that	that	PRON
ajst-17673	42	28	of	of	ADP
ajst-17673	42	29	clopidogrel	clopidogrel	NOUN
ajst-17673	42	30	,	,	PUNCT
ajst-17673	42	31	and	and	CCONJ
ajst-17673	42	32	the	the	DET
ajst-17673	42	33	differences	difference	NOUN
ajst-17673	42	34	between	between	ADP
ajst-17673	42	35	the	the	DET
ajst-17673	42	36	two	two	NUM
ajst-17673	42	37	groups	group	NOUN
ajst-17673	42	38	in	in	ADP
ajst-17673	42	39	terms	term	NOUN
ajst-17673	42	40	of	of	ADP
ajst-17673	42	41	gender	gender	NOUN
ajst-17673	42	42	,	,	PUNCT
ajst-17673	42	43	smoking	smoking	NOUN
ajst-17673	42	44	history	history	NOUN
ajst-17673	42	45	,	,	PUNCT
ajst-17673	42	46	history	history	NOUN
ajst-17673	42	47	of	of	ADP
ajst-17673	42	48	hypertension	hypertension	NOUN
ajst-17673	42	49	,	,	PUNCT
ajst-17673	42	50	history	history	NOUN
ajst-17673	42	51	of	of	ADP
ajst-17673	42	52	diabetes	diabetes	NOUN
ajst-17673	42	53	mellitus	mellitus	NOUN
ajst-17673	42	54	,	,	PUNCT
ajst-17673	42	55	and	and	CCONJ
ajst-17673	42	56	hyperlipidemia	hyperlipidemia	NOUN
ajst-17673	42	57	were	be	AUX
ajst-17673	42	58	not	not	PART
ajst-17673	42	59	statistically	statistically	ADV
ajst-17673	42	60	significant	significant	ADJ
ajst-17673	42	61	(	(	PUNCT
ajst-17673	42	62	p＞0.05	p＞0.05	NOUN
ajst-17673	42	63	)	)	PUNCT
ajst-17673	42	64	and	and	CCONJ
ajst-17673	42	65	comparable	comparable	ADJ
ajst-17673	42	66	,	,	PUNCT
ajst-17673	42	67	as	as	SCONJ
ajst-17673	42	68	can	can	AUX
ajst-17673	42	69	be	be	AUX
ajst-17673	42	70	seen	see	VERB
ajst-17673	42	71	in	in	ADP
ajst-17673	42	72	table	table	NOUN
ajst-17673	42	73	1	1	NUM
ajst-17673	42	74	.	.	PUNCT
ajst-17673	42	75	table	table	NOUN
ajst-17673	43	1	1	1	NUM
ajst-17673	43	2	.	.	PUNCT
ajst-17673	43	3	clinical	clinical	ADJ
ajst-17673	43	4	baseline	baseline	PROPN
ajst-17673	43	5	information	information	NOUN
ajst-17673	43	6	for	for	ADP
ajst-17673	43	7	older	old	ADJ
ajst-17673	43	8	adults	adult	NOUN
ajst-17673	43	9	characteristic	characteristic	ADJ
ajst-17673	43	10	clopidogrel	clopidogrel	NOUN
ajst-17673	43	11	（	（	PUNCT
ajst-17673	43	12	n=320	n=320	PROPN
ajst-17673	43	13	）	）	SYM
ajst-17673	43	14	ticagrelor	ticagrelor	NOUN
ajst-17673	43	15	（	（	SYM
ajst-17673	43	16	n=165	n=165	PROPN
ajst-17673	43	17	）	）	SYM
ajst-17673	43	18	t	t	PROPN
ajst-17673	43	19	/	/	SYM
ajst-17673	43	20	x²	x²	PROPN
ajst-17673	43	21	p	p	NOUN
ajst-17673	43	22	-	-	PUNCT
ajst-17673	43	23	value	value	NOUN
ajst-17673	43	24	age	age	NOUN
ajst-17673	43	25	74.9±6.3	74.9±6.3	NUM
ajst-17673	43	26	73.6±6.4	73.6±6.4	NUM
ajst-17673	43	27	2.13	2.13	NUM
ajst-17673	43	28	0.033	0.033	NUM
ajst-17673	43	29	male	male	ADJ
ajst-17673	43	30	144（44.2	144（44.2	NUM
ajst-17673	43	31	%	%	NOUN
ajst-17673	43	32	）	）	NOUN
ajst-17673	44	1	59（36.2	59（36.2	NUM
ajst-17673	44	2	%	%	NOUN
ajst-17673	44	3	）	）	NOUN
ajst-17673	45	1	2.85	2.85	NUM
ajst-17673	45	2	0.092	0.092	NUM
ajst-17673	45	3	hypertension	hypertension	NOUN
ajst-17673	45	4	252（77.3	252（77.3	NUM
ajst-17673	45	5	%	%	NOUN
ajst-17673	45	6	）	）	PUNCT
ajst-17673	46	1	121（74.2	121（74.2	NOUN
ajst-17673	47	1	%	%	NOUN
ajst-17673	47	2	）	）	SYM
ajst-17673	47	3	0.57	0.57	NUM
ajst-17673	47	4	0.452	0.452	NUM
ajst-17673	47	5	dm	dm	NUM
ajst-17673	47	6	110（34.6	110（34.6	NUM
ajst-17673	47	7	%	%	NOUN
ajst-17673	47	8	）	）	PUNCT
ajst-17673	48	1	57（35.4	57（35.4	NUM
ajst-17673	48	2	%	%	NOUN
ajst-17673	48	3	）	）	PROPN
ajst-17673	48	4	0.06	0.06	NUM
ajst-17673	48	5	0.805	0.805	NUM
ajst-17673	48	6	peptic	peptic	ADJ
ajst-17673	48	7	ulcer	ulcer	NOUN
ajst-17673	48	8	10	10	NUM
ajst-17673	48	9	（	（	SYM
ajst-17673	48	10	3.1	3.1	NUM
ajst-17673	48	11	%	%	NOUN
ajst-17673	48	12	）	）	NOUN
ajst-17673	48	13	3	3	NUM
ajst-17673	48	14	（	（	SYM
ajst-17673	48	15	1.8	1.8	NUM
ajst-17673	48	16	%	%	NOUN
ajst-17673	48	17	）	）	NOUN
ajst-17673	49	1	0.25	0.25	NUM
ajst-17673	49	2	0.619	0.619	NUM
ajst-17673	49	3	strokehistory	strokehistory	ADJ
ajst-17673	49	4	46（14.1	46（14.1	NUM
ajst-17673	49	5	%	%	NOUN
ajst-17673	49	6	）	）	PUNCT
ajst-17673	50	1	19（11.7	19（11.7	NUM
ajst-17673	51	1	%	%	NOUN
ajst-17673	51	2	）	）	SYM
ajst-17673	52	1	0.57	0.57	NUM
ajst-17673	52	2	0.451	0.451	NUM
ajst-17673	52	3	previous	previous	ADJ
ajst-17673	52	4	pci	pci	ADJ
ajst-17673	52	5	72（22.1	72（22.1	NUM
ajst-17673	52	6	%	%	NOUN
ajst-17673	52	7	）	）	PUNCT
ajst-17673	53	1	29（17.8	29（17.8	NUM
ajst-17673	53	2	%	%	NOUN
ajst-17673	53	3	）	）	NOUN
ajst-17673	53	4	1.22	1.22	NUM
ajst-17673	53	5	0.269	0.269	NUM
ajst-17673	53	6	smoking	smoking	NOUN
ajst-17673	53	7	history	history	NOUN
ajst-17673	53	8	5.24	5.24	NUM
ajst-17673	53	9	0.073	0.073	NUM
ajst-17673	53	10	non	non	ADJ
ajst-17673	53	11	-	-	ADJ
ajst-17673	53	12	smoker	smoker	ADJ
ajst-17673	53	13	247（75.8	247（75.8	NUM
ajst-17673	53	14	%	%	NOUN
ajst-17673	53	15	）	）	PUNCT
ajst-17673	54	1	108（66.3	108（66.3	NUM
ajst-17673	54	2	%	%	NOUN
ajst-17673	54	3	）	）	PUNCT
ajst-17673	54	4	quit	quit	VERB
ajst-17673	54	5	41（12.6	41（12.6	NUM
ajst-17673	54	6	%	%	NOUN
ajst-17673	54	7	）	）	PUNCT
ajst-17673	55	1	26（16	26（16	NUM
ajst-17673	55	2	%	%	NOUN
ajst-17673	55	3	）	）	PUNCT
ajst-17673	55	4	did	do	AUX
ajst-17673	55	5	not	not	PART
ajst-17673	55	6	quit	quit	VERB
ajst-17673	55	7	38（11.7	38（11.7	NUM
ajst-17673	55	8	%	%	NOUN
ajst-17673	55	9	）	）	PUNCT
ajst-17673	56	1	67（13.7	67（13.7	NUM
ajst-17673	57	1	%	%	NOUN
ajst-17673	57	2	）	）	PUNCT
ajst-17673	58	1	platelets	platelet	VERB
ajst-17673	58	2	213.4±59.3	213.4±59.3	NUM
ajst-17673	58	3	217.0±62.3	217.0±62.3	NOUN
ajst-17673	58	4	0.63	0.63	NUM
ajst-17673	58	5	0.527	0.527	NUM
ajst-17673	58	6	tc	tc	NUM
ajst-17673	58	7	4.8±1.5	4.8±1.5	NUM
ajst-17673	58	8	3.0±1.0	3.0±1.0	NUM
ajst-17673	58	9	0.96	0.96	NUM
ajst-17673	58	10	0.336	0.336	NUM
ajst-17673	58	11	ldl	ldl	PROPN
ajst-17673	58	12	-	-	PUNCT
ajst-17673	58	13	c	c	NOUN
ajst-17673	58	14	2.7±1.0	2.7±1.0	NUM
ajst-17673	58	15	2.8±0.8	2.8±0.8	NUM
ajst-17673	58	16	1.79	1.79	NUM
ajst-17673	58	17	0.075	0.075	NUM
ajst-17673	58	18	tg	tg	PROPN
ajst-17673	58	19	1.57±1.04	1.57±1.04	NUM
ajst-17673	58	20	1.74±1.88	1.74±1.88	PROPN
ajst-17673	58	21	1.27	1.27	NUM
ajst-17673	58	22	0.205	0.205	NUM
ajst-17673	58	23	lvef	lvef	NOUN
ajst-17673	59	1	57.1±11.6	57.1±11.6	PROPN
ajst-17673	59	2	56.3±12.9	56.3±12.9	NUM
ajst-17673	59	3	0.61	0.61	NUM
ajst-17673	59	4	0.543	0.543	NUM
ajst-17673	59	5	medication	medication	NOUN
ajst-17673	59	6	statin	statin	ADJ
ajst-17673	59	7	316（96.9	316（96.9	NUM
ajst-17673	59	8	%	%	NOUN
ajst-17673	59	9	）	）	NOUN
ajst-17673	60	1	157（96.3	157（96.3	NOUN
ajst-17673	60	2	%	%	NOUN
ajst-17673	60	3	）	）	PROPN
ajst-17673	61	1	0.13	0.13	NUM
ajst-17673	61	2	0.719	0.719	NUM
ajst-17673	61	3	betablocker	betablocker	NOUN
ajst-17673	61	4	254（79.5	254（79.5	NUM
ajst-17673	61	5	%	%	NOUN
ajst-17673	61	6	）	）	PUNCT
ajst-17673	61	7	134（82.2	134（82.2	NUM
ajst-17673	62	1	%	%	NOUN
ajst-17673	62	2	）	）	NOUN
ajst-17673	62	3	1.04	1.04	NUM
ajst-17673	62	4	0.208	0.208	NUM
ajst-17673	62	5	acei	acei	NOUN
ajst-17673	62	6	/	/	SYM
ajst-17673	62	7	arb	arb	PROPN
ajst-17673	62	8	233（71.5	233（71.5	NUM
ajst-17673	62	9	%	%	NOUN
ajst-17673	62	10	）	）	PUNCT
ajst-17673	63	1	119（73	119（73	NUM
ajst-17673	63	2	%	%	NOUN
ajst-17673	63	3	）	）	NOUN
ajst-17673	63	4	0.13	0.13	NUM
ajst-17673	63	5	0.722	0.722	NUM
ajst-17673	63	6	ccb	ccb	NOUN
ajst-17673	63	7	119（36.5	119（36.5	NUM
ajst-17673	64	1	%	%	NOUN
ajst-17673	64	2	）	）	PROPN
ajst-17673	65	1	51	51	NUM
ajst-17673	66	1	（	（	NUM
ajst-17673	66	2	31.3	31.3	NUM
ajst-17673	66	3	%	%	NOUN
ajst-17673	66	4	）	）	PROPN
ajst-17673	66	5	1.30	1.30	NUM
ajst-17673	66	6	0.254	0.254	NUM
ajst-17673	66	7	acei	acei	NOUN
ajst-17673	66	8	,	,	PUNCT
ajst-17673	66	9	angiotensin	angiotensin	NOUN
ajst-17673	66	10	-	-	PUNCT
ajst-17673	66	11	converting	convert	VERB
ajst-17673	66	12	enzyme	enzyme	NOUN
ajst-17673	66	13	inhibitor	inhibitor	NOUN
ajst-17673	66	14	;	;	PUNCT
ajst-17673	66	15	arb	arb	PROPN
ajst-17673	66	16	,	,	PUNCT
ajst-17673	66	17	angiotensin	angiotensin	NOUN
ajst-17673	66	18	receptor	receptor	NOUN
ajst-17673	66	19	blocker	blocker	NOUN
ajst-17673	66	20	;	;	PUNCT
ajst-17673	66	21	alt	alt	ADJ
ajst-17673	66	22	,	,	PUNCT
ajst-17673	66	23	alanine	alanine	PROPN
ajst-17673	66	24	transaminase;ast	transaminase;ast	NOUN
ajst-17673	66	25	,	,	PUNCT
ajst-17673	66	26	aspartate	aspartate	NOUN
ajst-17673	66	27	transaminase;dm	transaminase;dm	NOUN
ajst-17673	66	28	,	,	PUNCT
ajst-17673	66	29	diabetes	diabetes	NOUN
ajst-17673	66	30	mellitus	mellitus	NOUN
ajst-17673	66	31	;	;	PUNCT
ajst-17673	66	32	egfr	egfr	ADJ
ajst-17673	66	33	,	,	PUNCT
ajst-17673	66	34	estimate	estimate	VERB
ajst-17673	66	35	glomerular	glomerular	ADJ
ajst-17673	66	36	filtration	filtration	NOUN
ajst-17673	66	37	rate;ctni	rate;ctni	NOUN
ajst-17673	66	38	,	,	PUNCT
ajst-17673	66	39	cardiac	cardiac	ADJ
ajst-17673	66	40	troponin	troponin	ADJ
ajst-17673	66	41	i;ccb	i;ccb	PROPN
ajst-17673	66	42	,	,	PUNCT
ajst-17673	66	43	calcium	calcium	NOUN
ajst-17673	66	44	channel	channel	NOUN
ajst-17673	66	45	blocker;pci	blocker;pci	PROPN
ajst-17673	66	46	,	,	PUNCT
ajst-17673	66	47	percutaneous	percutaneous	ADJ
ajst-17673	66	48	coronary	coronary	ADJ
ajst-17673	66	49	intervention	intervention	NOUN
ajst-17673	66	50	;	;	PUNCT
ajst-17673	66	51	hdl	hdl	PROPN
ajst-17673	66	52	-	-	PUNCT
ajst-17673	66	53	c	c	PROPN
ajst-17673	66	54	,	,	PUNCT
ajst-17673	66	55	high	high	ADJ
ajst-17673	66	56	-	-	PUNCT
ajst-17673	66	57	density	density	NOUN
ajst-17673	66	58	cholesterol	cholesterol	NOUN
ajst-17673	66	59	;	;	PUNCT
ajst-17673	66	60	ldl	ldl	NOUN
ajst-17673	66	61	-	-	PUNCT
ajst-17673	66	62	c	c	NOUN
ajst-17673	66	63	,	,	PUNCT
ajst-17673	66	64	low	low	ADJ
ajst-17673	66	65	density	density	NOUN
ajst-17673	66	66	cholesterol	cholesterol	NOUN
ajst-17673	66	67	;	;	PUNCT
ajst-17673	66	68	tc	tc	NUM
ajst-17673	66	69	,	,	PUNCT
ajst-17673	66	70	total	total	ADJ
ajst-17673	66	71	cholesterol	cholesterol	NOUN
ajst-17673	66	72	;	;	PUNCT
ajst-17673	66	73	tg	tg	PROPN
ajst-17673	66	74	,	,	PUNCT
ajst-17673	66	75	triglycerides	triglyceride	NOUN
ajst-17673	66	76	;	;	PUNCT
ajst-17673	66	77	lvef	lvef	NOUN
ajst-17673	66	78	,	,	PUNCT
ajst-17673	66	79	left	leave	VERB
ajst-17673	66	80	ventricular	ventricular	ADJ
ajst-17673	66	81	ejection	ejection	NOUN
ajst-17673	66	82	fraction	fraction	NOUN
ajst-17673	66	83	.	.	PUNCT
ajst-17673	67	1	3.2	3.2	NUM
ajst-17673	67	2	after	after	ADP
ajst-17673	67	3	1	1	NUM
ajst-17673	67	4	year	year	NOUN
ajst-17673	67	5	of	of	ADP
ajst-17673	67	6	follow	follow	NOUN
ajst-17673	67	7	-	-	PUNCT
ajst-17673	67	8	up	up	ADP
ajst-17673	67	9	observation	observation	NOUN
ajst-17673	67	10	,	,	PUNCT
ajst-17673	67	11	the	the	DET
ajst-17673	67	12	incidence	incidence	NOUN
ajst-17673	67	13	rates	rate	NOUN
ajst-17673	67	14	of	of	ADP
ajst-17673	67	15	bleeding	bleed	VERB
ajst-17673	67	16	events	event	NOUN
ajst-17673	67	17	in	in	ADP
ajst-17673	67	18	patients	patient	NOUN
ajst-17673	67	19	treated	treat	VERB
ajst-17673	67	20	with	with	ADP
ajst-17673	67	21	tegretol	tegretol	NOUN
ajst-17673	67	22	and	and	CCONJ
ajst-17673	67	23	clopidogrel	clopidogrel	NOUN
ajst-17673	67	24	in	in	ADP
ajst-17673	67	25	the	the	DET
ajst-17673	67	26	two	two	NUM
ajst-17673	67	27	groups	group	NOUN
ajst-17673	67	28	were	be	AUX
ajst-17673	67	29	6.0	6.0	NUM
ajst-17673	67	30	%	%	NOUN
ajst-17673	67	31	and	and	CCONJ
ajst-17673	67	32	3.4	3.4	NUM
ajst-17673	67	33	%	%	NOUN
ajst-17673	67	34	,	,	PUNCT
ajst-17673	67	35	respectively	respectively	ADV
ajst-17673	67	36	,	,	PUNCT
ajst-17673	67	37	with	with	ADP
ajst-17673	67	38	tegretol	tegretol	NOUN
ajst-17673	67	39	slightly	slightly	ADV
ajst-17673	67	40	higher	high	ADJ
ajst-17673	67	41	than	than	ADP
ajst-17673	67	42	clopidogrel	clopidogrel	NOUN
ajst-17673	67	43	,	,	PUNCT
ajst-17673	67	44	and	and	CCONJ
ajst-17673	67	45	the	the	DET
ajst-17673	67	46	difference	difference	NOUN
ajst-17673	67	47	was	be	AUX
ajst-17673	67	48	not	not	PART
ajst-17673	67	49	statistically	statistically	ADV
ajst-17673	67	50	significant	significant	ADJ
ajst-17673	67	51	(	(	PUNCT
ajst-17673	67	52	p=0.179	p=0.179	NOUN
ajst-17673	67	53	)	)	PUNCT
ajst-17673	67	54	.	.	PUNCT
ajst-17673	68	1	the	the	DET
ajst-17673	68	2	incidence	incidence	NOUN
ajst-17673	68	3	rates	rate	NOUN
ajst-17673	68	4	of	of	ADP
ajst-17673	68	5	ischemic	ischemic	ADJ
ajst-17673	68	6	events	event	NOUN
ajst-17673	68	7	were	be	AUX
ajst-17673	68	8	28.5	28.5	NUM
ajst-17673	68	9	%	%	NOUN
ajst-17673	68	10	and	and	CCONJ
ajst-17673	68	11	26.3	26.3	NUM
ajst-17673	68	12	%	%	NOUN
ajst-17673	68	13	respectively	respectively	ADV
ajst-17673	68	14	,	,	PUNCT
ajst-17673	68	15	including	include	VERB
ajst-17673	68	16	12	12	NUM
ajst-17673	68	17	cases	case	NOUN
ajst-17673	68	18	of	of	ADP
ajst-17673	68	19	cardiac	cardiac	ADJ
ajst-17673	68	20	death	death	NOUN
ajst-17673	68	21	,	,	PUNCT
ajst-17673	68	22	10	10	NUM
ajst-17673	68	23	cases	case	NOUN
ajst-17673	68	24	of	of	ADP
ajst-17673	68	25	cerebral	cerebral	ADJ
ajst-17673	68	26	infarction	infarction	NOUN
ajst-17673	68	27	,	,	PUNCT
ajst-17673	68	28	and	and	CCONJ
ajst-17673	68	29	4	4	NUM
ajst-17673	68	30	cases	case	NOUN
ajst-17673	68	31	of	of	ADP
ajst-17673	68	32	myocardial	myocardial	ADJ
ajst-17673	68	33	infarction	infarction	NOUN
ajst-17673	68	34	,	,	PUNCT
ajst-17673	68	35	but	but	CCONJ
ajst-17673	68	36	there	there	PRON
ajst-17673	68	37	was	be	VERB
ajst-17673	68	38	no	no	DET
ajst-17673	68	39	statistically	statistically	ADV
ajst-17673	68	40	significant	significant	ADJ
ajst-17673	68	41	difference	difference	NOUN
ajst-17673	68	42	in	in	ADP
ajst-17673	68	43	the	the	DET
ajst-17673	68	44	rates	rate	NOUN
ajst-17673	68	45	of	of	ADP
ajst-17673	68	46	ischemic	ischemic	ADJ
ajst-17673	68	47	events	event	NOUN
ajst-17673	68	48	between	between	ADP
ajst-17673	68	49	the	the	DET
ajst-17673	68	50	two	two	NUM
ajst-17673	68	51	groups	group	NOUN
ajst-17673	68	52	(	(	PUNCT
ajst-17673	68	53	p=0.599	p=0.599	NUM
ajst-17673	68	54	)	)	PUNCT
ajst-17673	68	55	,	,	PUNCT
ajst-17673	68	56	see	see	VERB
ajst-17673	68	57	table	table	NOUN
ajst-17673	68	58	2	2	NUM
ajst-17673	68	59	.	.	X
ajst-17673	68	60	96	96	NUM
ajst-17673	68	61	table	table	NOUN
ajst-17673	68	62	2	2	NUM
ajst-17673	68	63	.	.	PUNCT
ajst-17673	68	64	primary	primary	ADJ
ajst-17673	68	65	endpoints	endpoint	NOUN
ajst-17673	68	66	,	,	PUNCT
ajst-17673	68	67	secondary	secondary	ADJ
ajst-17673	68	68	endpoints	endpoint	NOUN
ajst-17673	68	69	,	,	PUNCT
ajst-17673	68	70	and	and	CCONJ
ajst-17673	68	71	safety	safety	NOUN
ajst-17673	68	72	endpoint	endpoint	NOUN
ajst-17673	68	73	events	event	NOUN
ajst-17673	68	74	in	in	ADP
ajst-17673	68	75	older	old	ADJ
ajst-17673	68	76	adults	adult	NOUN
ajst-17673	68	77	events	event	NOUN
ajst-17673	68	78	clopidogrel(n=320	clopidogrel(n=320	NOUN
ajst-17673	68	79	)	)	PUNCT
ajst-17673	68	80	ticagrelor(n=165	ticagrelor(n=165	PROPN
ajst-17673	68	81	)	)	PUNCT
ajst-17673	68	82	x²	x²	PROPN
ajst-17673	68	83	p	p	NOUN
ajst-17673	68	84	-	-	PUNCT
ajst-17673	68	85	value	value	NOUN
ajst-17673	68	86	ischemic	ischemic	ADJ
ajst-17673	68	87	events	event	NOUN
ajst-17673	68	88	primary	primary	ADJ
ajst-17673	68	89	endpoint	endpoint	NOUN
ajst-17673	68	90	cardiac	cardiac	ADJ
ajst-17673	68	91	death	death	NOUN
ajst-17673	68	92	nonfatal	nonfatal	ADJ
ajst-17673	68	93	infarction	infarction	NOUN
ajst-17673	68	94	ischemic	ischemic	ADJ
ajst-17673	68	95	stroke	stroke	NOUN
ajst-17673	68	96	secondary	secondary	ADJ
ajst-17673	68	97	endpoint	endpoint	PROPN
ajst-17673	68	98	unstable	unstable	ADJ
ajst-17673	68	99	chest	chest	NOUN
ajst-17673	68	100	pain	pain	NOUN
ajst-17673	68	101	tvr	tvr	NOUN
ajst-17673	68	102	in	in	ADP
ajst-17673	68	103	-	-	PUNCT
ajst-17673	68	104	stent	stent	NOUN
ajst-17673	68	105	restenosis	restenosis	NOUN
ajst-17673	68	106	all	all	DET
ajst-17673	68	107	-	-	PUNCT
ajst-17673	68	108	cause	cause	NOUN
ajst-17673	68	109	mortality	mortality	NOUN
ajst-17673	68	110	bleeding	bleed	VERB
ajst-17673	68	111	events	event	NOUN
ajst-17673	68	112	bleeding	bleed	VERB
ajst-17673	68	113	84(26.3	84(26.3	NUM
ajst-17673	68	114	%	%	NOUN
ajst-17673	68	115	)	)	PUNCT
ajst-17673	68	116	7(2.2	7(2.2	NUM
ajst-17673	68	117	%	%	NOUN
ajst-17673	68	118	)	)	PUNCT
ajst-17673	68	119	1(0.3	1(0.3	NUM
ajst-17673	68	120	%	%	NOUN
ajst-17673	68	121	)	)	PUNCT
ajst-17673	68	122	8(2.5	8(2.5	NUM
ajst-17673	68	123	%	%	NOUN
ajst-17673	68	124	)	)	PUNCT
ajst-17673	68	125	52(16.3	52(16.3	NUM
ajst-17673	68	126	%	%	NOUN
ajst-17673	68	127	)	)	PUNCT
ajst-17673	68	128	12(3.8	12(3.8	NUM
ajst-17673	68	129	%	%	NOUN
ajst-17673	68	130	)	)	PUNCT
ajst-17673	68	131	4(1.3	4(1.3	NUM
ajst-17673	68	132	%	%	NOUN
ajst-17673	68	133	)	)	PUNCT
ajst-17673	68	134	5(1.6	5(1.6	NUM
ajst-17673	68	135	%	%	NOUN
ajst-17673	68	136	)	)	PUNCT
ajst-17673	68	137	11(3.4	11(3.4	NUM
ajst-17673	68	138	%	%	NOUN
ajst-17673	68	139	)	)	PUNCT
ajst-17673	69	1	47(28.5	47(28.5	NUM
ajst-17673	69	2	%	%	NOUN
ajst-17673	69	3	)	)	PUNCT
ajst-17673	69	4	5(3.0	5(3.0	NUM
ajst-17673	69	5	%	%	NOUN
ajst-17673	69	6	)	)	PUNCT
ajst-17673	70	1	3(1.8	3(1.8	NUM
ajst-17673	70	2	%	%	NOUN
ajst-17673	70	3	)	)	PUNCT
ajst-17673	70	4	2(1.2	2(1.2	NUM
ajst-17673	70	5	%	%	NOUN
ajst-17673	70	6	)	)	PUNCT
ajst-17673	70	7	24(14.5	24(14.5	NUM
ajst-17673	70	8	%	%	NOUN
ajst-17673	70	9	)	)	PUNCT
ajst-17673	70	10	11(6.7	11(6.7	NUM
ajst-17673	70	11	%	%	NOUN
ajst-17673	70	12	)	)	PUNCT
ajst-17673	70	13	2(1.2	2(1.2	NUM
ajst-17673	70	14	%	%	NOUN
ajst-17673	70	15	)	)	PUNCT
ajst-17673	70	16	3(1.8	3(1.8	NUM
ajst-17673	70	17	%	%	NOUN
ajst-17673	70	18	)	)	PUNCT
ajst-17673	70	19	10(6	10(6	NUM
ajst-17673	70	20	%	%	NOUN
ajst-17673	70	21	)	)	PUNCT
ajst-17673	70	22	0.28	0.28	NUM
ajst-17673	70	23	0.07	0.07	NUM
ajst-17673	70	24	1.46	1.46	NUM
ajst-17673	70	25	0.37	0.37	NUM
ajst-17673	70	26	0.24	0.24	NUM
ajst-17673	70	27	2.05	2.05	NUM
ajst-17673	70	28	0.00	0.00	NUM
ajst-17673	70	29	0.00	0.00	NUM
ajst-17673	70	30	1.81	1.81	NUM
ajst-17673	70	31	0.599	0.599	NUM
ajst-17673	70	32	0.797	0.797	NUM
ajst-17673	70	33	0.227	0.227	NUM
ajst-17673	70	34	0.543	0.543	NUM
ajst-17673	70	35	0.625	0.625	NUM
ajst-17673	70	36	0.152	0.152	NUM
ajst-17673	70	37	1.000	1.000	NUM
ajst-17673	70	38	1.000	1.000	NUM
ajst-17673	70	39	0.179	0.179	NUM
ajst-17673	70	40	tvr	tvr	NOUN
ajst-17673	70	41	,	,	PUNCT
ajst-17673	70	42	target	target	NOUN
ajst-17673	70	43	vessel	vessel	NOUN
ajst-17673	70	44	revascularization	revascularization	NOUN
ajst-17673	70	45	4	4	NUM
ajst-17673	70	46	.	.	PUNCT
ajst-17673	70	47	discussion	discussion	NOUN
ajst-17673	70	48	dual	dual	ADJ
ajst-17673	70	49	antiplatelet	antiplatelet	NOUN
ajst-17673	70	50	therapy	therapy	NOUN
ajst-17673	70	51	for	for	ADP
ajst-17673	70	52	acs	acs	PROPN
ajst-17673	70	53	has	have	AUX
ajst-17673	70	54	been	be	AUX
ajst-17673	70	55	the	the	DET
ajst-17673	70	56	current	current	ADJ
ajst-17673	70	57	classic	classic	ADJ
ajst-17673	70	58	treatment	treatment	NOUN
ajst-17673	70	59	strategy	strategy	NOUN
ajst-17673	70	60	,	,	PUNCT
ajst-17673	70	61	at	at	ADP
ajst-17673	70	62	present	present	ADJ
ajst-17673	70	63	clopidogrel	clopidogrel	NOUN
ajst-17673	70	64	is	be	AUX
ajst-17673	70	65	still	still	ADV
ajst-17673	70	66	the	the	PRON
ajst-17673	70	67	most	most	ADV
ajst-17673	70	68	widely	widely	ADV
ajst-17673	70	69	used	use	VERB
ajst-17673	70	70	p2y12	p2y12	NOUN
ajst-17673	70	71	(	(	PUNCT
ajst-17673	70	72	purinergic	purinergic	NOUN
ajst-17673	70	73	receptor	receptor	NOUN
ajst-17673	70	74	)	)	PUNCT
ajst-17673	70	75	p2y12	p2y12	VERB
ajst-17673	70	76	inhibitor	inhibitor	NOUN
ajst-17673	70	77	in	in	ADP
ajst-17673	70	78	china	china	PROPN
ajst-17673	70	79	,	,	PUNCT
ajst-17673	70	80	china	china	PROPN
ajst-17673	70	81	's	's	PART
ajst-17673	70	82	cardiovascular	cardiovascular	ADJ
ajst-17673	70	83	disease	disease	NOUN
ajst-17673	70	84	prevention	prevention	NOUN
ajst-17673	70	85	guidelines	guideline	NOUN
ajst-17673	70	86	and	and	CCONJ
ajst-17673	70	87	so	so	ADV
ajst-17673	70	88	on	on	ADV
ajst-17673	70	89	are	be	AUX
ajst-17673	70	90	still	still	ADV
ajst-17673	70	91	prioritized	prioritize	VERB
ajst-17673	70	92	clopidogrel	clopidogrel	NOUN
ajst-17673	70	93	.	.	PUNCT
ajst-17673	71	1	based	base	VERB
ajst-17673	71	2	on	on	ADP
ajst-17673	71	3	the	the	DET
ajst-17673	71	4	results	result	NOUN
ajst-17673	71	5	of	of	ADP
ajst-17673	71	6	the	the	DET
ajst-17673	71	7	triton	triton	PROPN
ajst-17673	71	8	-	-	PUNCT
ajst-17673	71	9	timi	timi	PROPN
ajst-17673	71	10	38	38	NUM
ajst-17673	71	11	trial	trial	NOUN
ajst-17673	71	12	and	and	CCONJ
ajst-17673	71	13	the	the	DET
ajst-17673	71	14	plato	plato	PROPN
ajst-17673	71	15	trial	trial	NOUN
ajst-17673	71	16	two	two	NUM
ajst-17673	71	17	studies	study	NOUN
ajst-17673	71	18	have	have	AUX
ajst-17673	71	19	shown	show	VERB
ajst-17673	71	20	that	that	SCONJ
ajst-17673	71	21	tegretol	tegretol	NOUN
ajst-17673	71	22	is	be	AUX
ajst-17673	71	23	superior	superior	ADJ
ajst-17673	71	24	to	to	ADP
ajst-17673	71	25	clopidogrel	clopidogrel	NOUN
ajst-17673	71	26	in	in	ADP
ajst-17673	71	27	reducing	reduce	VERB
ajst-17673	71	28	cardiovascular	cardiovascular	ADJ
ajst-17673	71	29	deaths	death	NOUN
ajst-17673	71	30	,	,	PUNCT
ajst-17673	71	31	myocardial	myocardial	ADJ
ajst-17673	71	32	infarction	infarction	NOUN
ajst-17673	71	33	,	,	PUNCT
ajst-17673	71	34	etc	etc	X
ajst-17673	71	35	.	.	X
ajst-17673	72	1	[	[	X
ajst-17673	72	2	10	10	NUM
ajst-17673	72	3	]	]	X
ajst-17673	73	1	[	[	X
ajst-17673	73	2	11	11	NUM
ajst-17673	73	3	]	]	PUNCT
ajst-17673	73	4	,	,	PUNCT
ajst-17673	73	5	but	but	CCONJ
ajst-17673	73	6	with	with	ADP
ajst-17673	73	7	advancing	advance	VERB
ajst-17673	73	8	age	age	NOUN
ajst-17673	73	9	,	,	PUNCT
ajst-17673	73	10	patients	patient	NOUN
ajst-17673	73	11	are	be	AUX
ajst-17673	73	12	at	at	ADP
ajst-17673	73	13	a	a	DET
ajst-17673	73	14	higher	high	ADJ
ajst-17673	73	15	risk	risk	NOUN
ajst-17673	73	16	of	of	ADP
ajst-17673	73	17	hemorrhagic	hemorrhagic	NOUN
ajst-17673	73	18	and	and	CCONJ
ajst-17673	73	19	thrombotic	thrombotic	ADJ
ajst-17673	73	20	events	event	NOUN
ajst-17673	73	21	,	,	PUNCT
ajst-17673	73	22	which	which	PRON
ajst-17673	73	23	makes	make	VERB
ajst-17673	73	24	the	the	DET
ajst-17673	73	25	optimal	optimal	ADJ
ajst-17673	73	26	choice	choice	NOUN
ajst-17673	73	27	of	of	ADP
ajst-17673	73	28	antithrombotic	antithrombotic	ADJ
ajst-17673	73	29	therapy	therapy	NOUN
ajst-17673	73	30	challenging	challenge	VERB
ajst-17673	73	31	[	[	X
ajst-17673	73	32	12	12	NUM
ajst-17673	73	33	]	]	X
ajst-17673	74	1	[	[	X
ajst-17673	74	2	13	13	NUM
ajst-17673	74	3	]	]	PUNCT
ajst-17673	74	4	.	.	PUNCT
ajst-17673	75	1	although	although	SCONJ
ajst-17673	75	2	current	current	ADJ
ajst-17673	75	3	guidelines	guideline	NOUN
ajst-17673	75	4	recommend	recommend	VERB
ajst-17673	75	5	tegretol	tegretol	NOUN
ajst-17673	75	6	as	as	ADP
ajst-17673	75	7	the	the	DET
ajst-17673	75	8	first	first	ADJ
ajst-17673	75	9	choice	choice	NOUN
ajst-17673	75	10	of	of	ADP
ajst-17673	75	11	antithrombotic	antithrombotic	ADJ
ajst-17673	75	12	in	in	ADP
ajst-17673	75	13	patients	patient	NOUN
ajst-17673	75	14	with	with	ADP
ajst-17673	75	15	acs	acs	PROPN
ajst-17673	75	16	[	[	X
ajst-17673	75	17	14	14	NUM
ajst-17673	75	18	]	]	PUNCT
ajst-17673	75	19	.	.	PUNCT
ajst-17673	76	1	however	however	ADV
ajst-17673	76	2	,	,	PUNCT
ajst-17673	76	3	large	large	ADJ
ajst-17673	76	4	-	-	PUNCT
ajst-17673	76	5	scale	scale	NOUN
ajst-17673	76	6	,	,	PUNCT
ajst-17673	76	7	multicenter	multicenter	ADJ
ajst-17673	76	8	evidence	evidence	NOUN
ajst-17673	76	9	-	-	PUNCT
ajst-17673	76	10	based	base	VERB
ajst-17673	76	11	studies	study	NOUN
ajst-17673	76	12	have	have	AUX
ajst-17673	76	13	been	be	AUX
ajst-17673	76	14	conducted	conduct	VERB
ajst-17673	76	15	mainly	mainly	ADV
ajst-17673	76	16	in	in	ADP
ajst-17673	76	17	developed	developed	ADJ
ajst-17673	76	18	countries	country	NOUN
ajst-17673	76	19	in	in	ADP
ajst-17673	76	20	europe	europe	PROPN
ajst-17673	76	21	and	and	CCONJ
ajst-17673	76	22	the	the	DET
ajst-17673	76	23	united	united	PROPN
ajst-17673	76	24	states	states	PROPN
ajst-17673	76	25	,	,	PUNCT
ajst-17673	76	26	and	and	CCONJ
ajst-17673	76	27	east	east	ADJ
ajst-17673	76	28	asian	asian	ADJ
ajst-17673	76	29	populations	population	NOUN
ajst-17673	76	30	may	may	AUX
ajst-17673	76	31	have	have	VERB
ajst-17673	76	32	a	a	DET
ajst-17673	76	33	higher	high	ADJ
ajst-17673	76	34	risk	risk	NOUN
ajst-17673	76	35	of	of	ADP
ajst-17673	76	36	stroke	stroke	NOUN
ajst-17673	76	37	than	than	ADP
ajst-17673	76	38	western	western	ADJ
ajst-17673	76	39	populations	population	NOUN
ajst-17673	76	40	[	[	X
ajst-17673	76	41	15	15	NUM
ajst-17673	76	42	]	]	PUNCT
ajst-17673	76	43	.	.	PUNCT
ajst-17673	77	1	moreover	moreover	ADV
ajst-17673	77	2	,	,	PUNCT
ajst-17673	77	3	some	some	DET
ajst-17673	77	4	studies	study	NOUN
ajst-17673	77	5	have	have	AUX
ajst-17673	77	6	shown	show	VERB
ajst-17673	77	7	that	that	SCONJ
ajst-17673	77	8	the	the	DET
ajst-17673	77	9	problem	problem	NOUN
ajst-17673	77	10	of	of	ADP
ajst-17673	77	11	insufficiency	insufficiency	NOUN
ajst-17673	77	12	is	be	AUX
ajst-17673	77	13	more	more	ADV
ajst-17673	77	14	prominent	prominent	ADJ
ajst-17673	77	15	in	in	ADP
ajst-17673	77	16	elderly	elderly	ADJ
ajst-17673	77	17	patients	patient	NOUN
ajst-17673	77	18	[	[	X
ajst-17673	77	19	16	16	NUM
ajst-17673	77	20	]	]	PUNCT
ajst-17673	77	21	.	.	PUNCT
ajst-17673	78	1	therefore	therefore	ADV
ajst-17673	78	2	,	,	PUNCT
ajst-17673	78	3	when	when	SCONJ
ajst-17673	78	4	choosing	choose	VERB
ajst-17673	78	5	an	an	DET
ajst-17673	78	6	antiplatelet	antiplatelet	NOUN
ajst-17673	78	7	regimen	regiman	NOUN
ajst-17673	78	8	for	for	ADP
ajst-17673	78	9	elderly	elderly	ADJ
ajst-17673	78	10	acs	acs	NOUN
ajst-17673	78	11	patients	patient	NOUN
ajst-17673	78	12	,	,	PUNCT
ajst-17673	78	13	it	it	PRON
ajst-17673	78	14	is	be	AUX
ajst-17673	78	15	important	important	ADJ
ajst-17673	78	16	to	to	PART
ajst-17673	78	17	reduce	reduce	VERB
ajst-17673	78	18	both	both	DET
ajst-17673	78	19	thrombotic	thrombotic	ADJ
ajst-17673	78	20	risk	risk	NOUN
ajst-17673	78	21	and	and	CCONJ
ajst-17673	78	22	bleeding	bleed	VERB
ajst-17673	78	23	risk	risk	NOUN
ajst-17673	78	24	.	.	PUNCT
ajst-17673	79	1	in	in	ADP
ajst-17673	79	2	conclusion	conclusion	NOUN
ajst-17673	79	3	,	,	PUNCT
ajst-17673	79	4	the	the	DET
ajst-17673	79	5	results	result	NOUN
ajst-17673	79	6	of	of	ADP
ajst-17673	79	7	this	this	DET
ajst-17673	79	8	study	study	NOUN
ajst-17673	79	9	did	do	AUX
ajst-17673	79	10	not	not	PART
ajst-17673	79	11	show	show	VERB
ajst-17673	79	12	a	a	DET
ajst-17673	79	13	significant	significant	ADJ
ajst-17673	79	14	survival	survival	NOUN
ajst-17673	79	15	benefit	benefit	NOUN
ajst-17673	79	16	of	of	ADP
ajst-17673	79	17	tegretol	tegretol	NOUN
ajst-17673	79	18	over	over	ADP
ajst-17673	79	19	clopidogrel	clopidogrel	NOUN
ajst-17673	79	20	,	,	PUNCT
ajst-17673	79	21	but	but	CCONJ
ajst-17673	79	22	it	it	PRON
ajst-17673	79	23	also	also	ADV
ajst-17673	79	24	did	do	AUX
ajst-17673	79	25	not	not	PART
ajst-17673	79	26	show	show	VERB
ajst-17673	79	27	a	a	DET
ajst-17673	79	28	significant	significant	ADJ
ajst-17673	79	29	increase	increase	NOUN
ajst-17673	79	30	in	in	ADP
ajst-17673	79	31	the	the	DET
ajst-17673	79	32	risk	risk	NOUN
ajst-17673	79	33	of	of	ADP
ajst-17673	79	34	hemorrhage	hemorrhage	NOUN
ajst-17673	79	35	.	.	PUNCT
ajst-17673	80	1	limitations	limitation	NOUN
ajst-17673	80	2	of	of	ADP
ajst-17673	80	3	this	this	DET
ajst-17673	80	4	study	study	NOUN
ajst-17673	80	5	:	:	PUNCT
ajst-17673	80	6	the	the	DET
ajst-17673	80	7	trial	trial	NOUN
ajst-17673	80	8	population	population	NOUN
ajst-17673	80	9	was	be	AUX
ajst-17673	80	10	small	small	ADJ
ajst-17673	80	11	,	,	PUNCT
ajst-17673	80	12	and	and	CCONJ
ajst-17673	80	13	it	it	PRON
ajst-17673	80	14	was	be	AUX
ajst-17673	80	15	a	a	DET
ajst-17673	80	16	single	single	ADJ
ajst-17673	80	17	-	-	PUNCT
ajst-17673	80	18	center	center	NOUN
ajst-17673	80	19	,	,	PUNCT
ajst-17673	80	20	only	only	ADV
ajst-17673	80	21	regional	regional	ADJ
ajst-17673	80	22	study	study	NOUN
ajst-17673	80	23	,	,	PUNCT
ajst-17673	80	24	and	and	CCONJ
ajst-17673	80	25	there	there	PRON
ajst-17673	80	26	are	be	VERB
ajst-17673	80	27	still	still	ADV
ajst-17673	80	28	fewer	few	ADJ
ajst-17673	80	29	large	large	ADJ
ajst-17673	80	30	-	-	PUNCT
ajst-17673	80	31	scale	scale	NOUN
ajst-17673	80	32	clinical	clinical	ADJ
ajst-17673	80	33	trials	trial	NOUN
ajst-17673	80	34	of	of	ADP
ajst-17673	80	35	tegretol	tegretol	NOUN
ajst-17673	80	36	and	and	CCONJ
ajst-17673	80	37	clopidogrel	clopidogrel	NOUN
ajst-17673	80	38	in	in	ADP
ajst-17673	80	39	china	china	PROPN
ajst-17673	80	40	for	for	ADP
ajst-17673	80	41	patients	patient	NOUN
ajst-17673	80	42	with	with	ADP
ajst-17673	80	43	acs	acs	PROPN
ajst-17673	80	44	in	in	ADP
ajst-17673	80	45	their	their	PRON
ajst-17673	80	46	own	own	ADJ
ajst-17673	80	47	country	country	NOUN
ajst-17673	80	48	,	,	PUNCT
ajst-17673	80	49	so	so	ADV
ajst-17673	80	50	more	more	ADV
ajst-17673	80	51	large	large	ADJ
ajst-17673	80	52	-	-	PUNCT
ajst-17673	80	53	scale	scale	NOUN
ajst-17673	80	54	,	,	PUNCT
ajst-17673	80	55	multicenter	multicenter	ADJ
ajst-17673	80	56	clinical	clinical	ADJ
ajst-17673	80	57	studies	study	NOUN
ajst-17673	80	58	are	be	AUX
ajst-17673	80	59	needed	need	VERB
ajst-17673	80	60	to	to	PART
ajst-17673	80	61	confirm	confirm	VERB
ajst-17673	80	62	this	this	PRON
ajst-17673	80	63	.	.	PUNCT
ajst-17673	81	1	5	5	X
ajst-17673	81	2	.	.	X
ajst-17673	81	3	conclusion	conclusion	NOUN
ajst-17673	81	4	in	in	ADP
ajst-17673	81	5	elderly	elderly	ADJ
ajst-17673	81	6	patients	patient	NOUN
ajst-17673	81	7	with	with	ADP
ajst-17673	81	8	cyp2c19	cyp2c19	NOUN
ajst-17673	81	9	-	-	PUNCT
ajst-17673	81	10	directed	direct	VERB
ajst-17673	81	11	acs	ac	NOUN
ajst-17673	81	12	,	,	PUNCT
ajst-17673	81	13	there	there	PRON
ajst-17673	81	14	was	be	VERB
ajst-17673	81	15	no	no	DET
ajst-17673	81	16	significant	significant	ADJ
ajst-17673	81	17	difference	difference	NOUN
ajst-17673	81	18	in	in	ADP
ajst-17673	81	19	survival	survival	NOUN
ajst-17673	81	20	prognosis	prognosis	NOUN
ajst-17673	81	21	,	,	PUNCT
ajst-17673	81	22	ischemic	ischemic	ADJ
ajst-17673	81	23	events	event	NOUN
ajst-17673	81	24	,	,	PUNCT
ajst-17673	81	25	or	or	CCONJ
ajst-17673	81	26	bleeding	bleed	VERB
ajst-17673	81	27	risk	risk	NOUN
ajst-17673	81	28	between	between	ADP
ajst-17673	81	29	tegretol	tegretol	NOUN
ajst-17673	81	30	and	and	CCONJ
ajst-17673	81	31	clopidogrel	clopidogrel	NOUN
ajst-17673	81	32	at	at	ADP
ajst-17673	81	33	1	1	NUM
ajst-17673	81	34	year	year	NOUN
ajst-17673	81	35	.	.	PUNCT
ajst-17673	82	1	acknowledgment	acknowledgment	NOUN
ajst-17673	82	2	we	we	PRON
ajst-17673	82	3	're	be	AUX
ajst-17673	82	4	very	very	ADV
ajst-17673	82	5	grateful	grateful	ADJ
ajst-17673	82	6	to	to	ADP
ajst-17673	82	7	my	my	PRON
ajst-17673	82	8	good	good	ADJ
ajst-17673	82	9	friends	friend	NOUN
ajst-17673	82	10	yang	yang	PROPN
ajst-17673	82	11	sen	sen	PROPN
ajst-17673	82	12	and	and	CCONJ
ajst-17673	82	13	pang	pang	PROPN
ajst-17673	82	14	zhiqin	zhiqin	PROPN
ajst-17673	82	15	for	for	ADP
ajst-17673	82	16	their	their	PRON
ajst-17673	82	17	help	help	NOUN
ajst-17673	82	18	.	.	PUNCT
ajst-17673	83	1	references	reference	NOUN
ajst-17673	83	2	[	[	X
ajst-17673	83	3	1	1	NUM
ajst-17673	83	4	]	]	PUNCT
ajst-17673	83	5	m.	m.	NOUN
ajst-17673	83	6	valgimigli	valgimigli	PROPN
ajst-17673	83	7	,	,	PUNCT
ajst-17673	83	8	h.	h.	PROPN
ajst-17673	83	9	bueno	bueno	PROPN
ajst-17673	83	10	,	,	PUNCT
ajst-17673	83	11	r.a	r.a	PROPN
ajst-17673	83	12	.	.	PROPN
ajst-17673	83	13	byrne	byrne	PROPN
ajst-17673	83	14	,	,	PUNCT
ajst-17673	83	15	et	et	PROPN
ajst-17673	83	16	al.2017	al.2017	PROPN
ajst-17673	83	17	esc	esc	NOUN
ajst-17673	83	18	focused	focus	VERB
ajst-17673	83	19	update	update	NOUN
ajst-17673	83	20	on	on	ADP
ajst-17673	83	21	dual	dual	ADJ
ajst-17673	83	22	antiplatelet	antiplatelet	NOUN
ajst-17673	83	23	therapy	therapy	NOUN
ajst-17673	83	24	in	in	ADP
ajst-17673	83	25	coronary	coronary	ADJ
ajst-17673	83	26	artery	artery	NOUN
ajst-17673	83	27	disease	disease	NOUN
ajst-17673	83	28	developed	develop	VERB
ajst-17673	83	29	in	in	ADP
ajst-17673	83	30	collaboration	collaboration	NOUN
ajst-17673	83	31	with	with	ADP
ajst-17673	83	32	eacts	eact	NOUN
ajst-17673	83	33	:	:	PUNCT
ajst-17673	83	34	the	the	DET
ajst-17673	83	35	task	task	NOUN
ajst-17673	83	36	force	force	NOUN
ajst-17673	83	37	for	for	ADP
ajst-17673	83	38	dual	dual	ADJ
ajst-17673	83	39	antiplatelet	antiplatelet	NOUN
ajst-17673	83	40	therapy	therapy	NOUN
ajst-17673	83	41	in	in	ADP
ajst-17673	83	42	coronary	coronary	ADJ
ajst-17673	83	43	artery	artery	NOUN
ajst-17673	83	44	disease	disease	NOUN
ajst-17673	83	45	of	of	ADP
ajst-17673	83	46	the	the	DET
ajst-17673	83	47	european	european	ADJ
ajst-17673	83	48	society	society	PROPN
ajst-17673	83	49	of	of	ADP
ajst-17673	83	50	cardiology	cardiology	NOUN
ajst-17673	83	51	(	(	PUNCT
ajst-17673	83	52	esc	esc	NOUN
ajst-17673	83	53	)	)	PUNCT
ajst-17673	83	54	and	and	CCONJ
ajst-17673	83	55	of	of	ADP
ajst-17673	83	56	the	the	DET
ajst-17673	83	57	european	european	PROPN
ajst-17673	83	58	association	association	PROPN
ajst-17673	83	59	for	for	ADP
ajst-17673	83	60	cardio	cardio	NOUN
ajst-17673	83	61	-	-	PUNCT
ajst-17673	83	62	thoracic	thoracic	NOUN
ajst-17673	83	63	surgery	surgery	NOUN
ajst-17673	83	64	(	(	PUNCT
ajst-17673	83	65	eacts	eact	NOUN
ajst-17673	83	66	)	)	PUNCT
ajst-17673	83	67	eur	eur	PROPN
ajst-17673	83	68	heart	heart	PROPN
ajst-17673	83	69	j	j	PROPN
ajst-17673	83	70	,	,	PUNCT
ajst-17673	83	71	39	39	NUM
ajst-17673	83	72	(	(	PUNCT
ajst-17673	83	73	2018	2018	NUM
ajst-17673	83	74	)	)	PUNCT
ajst-17673	83	75	,	,	PUNCT
ajst-17673	83	76	pp	pp	PROPN
ajst-17673	83	77	.	.	PUNCT
ajst-17673	84	1	213	213	NUM
ajst-17673	84	2	-	-	SYM
ajst-17673	84	3	260	260	NUM
ajst-17673	84	4	[	[	X
ajst-17673	84	5	2	2	NUM
ajst-17673	84	6	]	]	X
ajst-17673	84	7	schomig	schomig	NOUN
ajst-17673	84	8	,	,	PUNCT
ajst-17673	84	9	f.j	f.j	PROPN
ajst-17673	84	10	.	.	PROPN
ajst-17673	84	11	neumann	neumann	PROPN
ajst-17673	84	12	,	,	PUNCT
ajst-17673	84	13	a.	a.	NOUN
ajst-17673	84	14	kastrati	kastrati	PROPN
ajst-17673	84	15	,	,	PUNCT
ajst-17673	84	16	et	et	NOUN
ajst-17673	84	17	al.a	al.a	NOUN
ajst-17673	84	18	randomized	randomize	VERB
ajst-17673	84	19	comparison	comparison	NOUN
ajst-17673	84	20	of	of	ADP
ajst-17673	84	21	antiplatelet	antiplatelet	NOUN
ajst-17673	84	22	and	and	CCONJ
ajst-17673	84	23	anticoagulant	anticoagulant	NOUN
ajst-17673	84	24	therapy	therapy	NOUN
ajst-17673	84	25	after	after	ADP
ajst-17673	84	26	the	the	DET
ajst-17673	84	27	placement	placement	NOUN
ajst-17673	84	28	of	of	ADP
ajst-17673	84	29	coronary	coronary	ADJ
ajst-17673	84	30	-	-	PUNCT
ajst-17673	84	31	artery	artery	NOUN
ajst-17673	84	32	stents	stent	NOUN
ajst-17673	84	33	n	n	CCONJ
ajst-17673	84	34	engl	engl	PROPN
ajst-17673	84	35	j	j	PROPN
ajst-17673	84	36	med	med	PROPN
ajst-17673	84	37	,	,	PUNCT
ajst-17673	84	38	334	334	NUM
ajst-17673	84	39	(	(	PUNCT
ajst-17673	84	40	1996	1996	NUM
ajst-17673	84	41	)	)	PUNCT
ajst-17673	84	42	,	,	PUNCT
ajst-17673	84	43	pp	pp	PROPN
ajst-17673	84	44	.	.	PUNCT
ajst-17673	85	1	1084	1084	NUM
ajst-17673	85	2	-	-	SYM
ajst-17673	85	3	1089	1089	NUM
ajst-17673	85	4	[	[	X
ajst-17673	85	5	3	3	NUM
ajst-17673	85	6	]	]	X
ajst-17673	85	7	p.a	p.a	PROPN
ajst-17673	85	8	.	.	PROPN
ajst-17673	85	9	gurbel	gurbel	PROPN
ajst-17673	85	10	,	,	PUNCT
ajst-17673	85	11	k.p	k.p	PROPN
ajst-17673	85	12	.	.	PROPN
ajst-17673	85	13	bliden	bliden	PROPN
ajst-17673	85	14	,	,	PUNCT
ajst-17673	85	15	b.l	b.l	PROPN
ajst-17673	85	16	.	.	PROPN
ajst-17673	85	17	hiatt	hiatt	PROPN
ajst-17673	85	18	,	,	PUNCT
ajst-17673	85	19	c.m	c.m	PROPN
ajst-17673	85	20	.	.	PROPN
ajst-17673	85	21	o’connor	o’connor	ADJ
ajst-17673	85	22	clopidogrel	clopidogrel	NOUN
ajst-17673	85	23	for	for	ADP
ajst-17673	85	24	coronary	coronary	ADJ
ajst-17673	85	25	stenting	stenting	NOUN
ajst-17673	85	26	:	:	PUNCT
ajst-17673	85	27	response	response	NOUN
ajst-17673	85	28	variability	variability	NOUN
ajst-17673	85	29	,	,	PUNCT
ajst-17673	85	30	drug	drug	NOUN
ajst-17673	85	31	resistance	resistance	NOUN
ajst-17673	85	32	,	,	PUNCT
ajst-17673	85	33	and	and	CCONJ
ajst-17673	85	34	the	the	DET
ajst-17673	85	35	effect	effect	NOUN
ajst-17673	85	36	of	of	ADP
ajst-17673	85	37	pretreatment	pretreatment	NOUN
ajst-17673	85	38	platelet	platelet	NOUN
ajst-17673	85	39	reactivity	reactivity	NOUN
ajst-17673	85	40	circulation	circulation	NOUN
ajst-17673	85	41	,	,	PUNCT
ajst-17673	85	42	107	107	NUM
ajst-17673	85	43	(	(	PUNCT
ajst-17673	85	44	2003	2003	NUM
ajst-17673	85	45	)	)	PUNCT
ajst-17673	85	46	,	,	PUNCT
ajst-17673	85	47	pp	pp	PROPN
ajst-17673	85	48	.	.	PUNCT
ajst-17673	86	1	2908	2908	NUM
ajst-17673	86	2	-	-	SYM
ajst-17673	86	3	2913	2913	NUM
ajst-17673	86	4	[	[	X
ajst-17673	86	5	4	4	NUM
ajst-17673	86	6	]	]	X
ajst-17673	86	7	j.l	j.l	PROPN
ajst-17673	86	8	.	.	PROPN
ajst-17673	86	9	mega	mega	PROPN
ajst-17673	86	10	,	,	PUNCT
ajst-17673	86	11	t.	t.	PROPN
ajst-17673	86	12	simon	simon	PROPN
ajst-17673	86	13	,	,	PUNCT
ajst-17673	86	14	j.p	j.p	PROPN
ajst-17673	86	15	.	.	PROPN
ajst-17673	86	16	collet	collet	PROPN
ajst-17673	86	17	,	,	PUNCT
ajst-17673	86	18	et	et	NOUN
ajst-17673	86	19	al.reduced	al.reduced	ADJ
ajst-17673	86	20	-	-	PUNCT
ajst-17673	86	21	function	function	NOUN
ajst-17673	86	22	cyp2c19	cyp2c19	NOUN
ajst-17673	86	23	genotype	genotype	NOUN
ajst-17673	86	24	and	and	CCONJ
ajst-17673	86	25	risk	risk	NOUN
ajst-17673	86	26	of	of	ADP
ajst-17673	86	27	adverse	adverse	ADJ
ajst-17673	86	28	clinical	clinical	ADJ
ajst-17673	86	29	outcomes	outcome	NOUN
ajst-17673	86	30	among	among	ADP
ajst-17673	86	31	patients	patient	NOUN
ajst-17673	86	32	treated	treat	VERB
ajst-17673	86	33	with	with	ADP
ajst-17673	86	34	clopidogrel	clopidogrel	NOUN
ajst-17673	86	35	predominantly	predominantly	ADV
ajst-17673	86	36	for	for	ADP
ajst-17673	86	37	pci	pci	ADJ
ajst-17673	86	38	:	:	PUNCT
ajst-17673	86	39	a	a	DET
ajst-17673	86	40	meta	meta	ADJ
ajst-17673	86	41	-	-	PUNCT
ajst-17673	86	42	analysis	analysis	NOUN
ajst-17673	86	43	jama	jama	NOUN
ajst-17673	86	44	,	,	PUNCT
ajst-17673	86	45	304	304	NUM
ajst-17673	86	46	(	(	PUNCT
ajst-17673	86	47	2010	2010	NUM
ajst-17673	86	48	)	)	PUNCT
ajst-17673	86	49	,	,	PUNCT
ajst-17673	86	50	pp	pp	PROPN
ajst-17673	86	51	.	.	PUNCT
ajst-17673	87	1	1821	1821	NUM
ajst-17673	87	2	-	-	SYM
ajst-17673	87	3	1830	1830	NUM
ajst-17673	87	4	[	[	X
ajst-17673	87	5	5	5	NUM
ajst-17673	87	6	]	]	X
ajst-17673	87	7	a.r	a.r	PROPN
ajst-17673	87	8	.	.	PROPN
ajst-17673	87	9	shuldiner	shuldiner	PROPN
ajst-17673	87	10	,	,	PUNCT
ajst-17673	87	11	j.r	j.r	PROPN
ajst-17673	87	12	.	.	PROPN
ajst-17673	87	13	o’connell	o’connell	PROPN
ajst-17673	87	14	,	,	PUNCT
ajst-17673	87	15	k.p	k.p	PROPN
ajst-17673	87	16	.	.	PROPN
ajst-17673	87	17	bliden	bliden	PROPN
ajst-17673	87	18	,	,	PUNCT
ajst-17673	87	19	et	et	NOUN
ajst-17673	87	20	al.association	al.association	NOUN
ajst-17673	87	21	of	of	ADP
ajst-17673	87	22	cytochrome	cytochrome	ADJ
ajst-17673	87	23	p450	p450	PROPN
ajst-17673	87	24	2c19	2c19	NOUN
ajst-17673	87	25	genotype	genotype	NOUN
ajst-17673	87	26	with	with	ADP
ajst-17673	87	27	the	the	DET
ajst-17673	87	28	antiplatelet	antiplatelet	NOUN
ajst-17673	87	29	effect	effect	NOUN
ajst-17673	87	30	and	and	CCONJ
ajst-17673	87	31	clinical	clinical	ADJ
ajst-17673	87	32	efficacy	efficacy	NOUN
ajst-17673	87	33	of	of	ADP
ajst-17673	87	34	clopidogrel	clopidogrel	NOUN
ajst-17673	87	35	therapyjama	therapyjama	NOUN
ajst-17673	87	36	,	,	PUNCT
ajst-17673	87	37	302	302	NUM
ajst-17673	87	38	(	(	PUNCT
ajst-17673	87	39	2009	2009	NUM
ajst-17673	87	40	)	)	PUNCT
ajst-17673	87	41	,	,	PUNCT
ajst-17673	87	42	pp	pp	PROPN
ajst-17673	87	43	.	.	PUNCT
ajst-17673	88	1	849	849	NUM
ajst-17673	88	2	-	-	SYM
ajst-17673	88	3	857	857	NUM
ajst-17673	88	4	[	[	PUNCT
ajst-17673	88	5	6	6	NUM
ajst-17673	88	6	]	]	PUNCT
ajst-17673	88	7	w.	w.	PROPN
ajst-17673	88	8	hochholzer	hochholzer	PROPN
ajst-17673	88	9	,	,	PUNCT
ajst-17673	88	10	d.	d.	PROPN
ajst-17673	88	11	trenk	trenk	PROPN
ajst-17673	88	12	,	,	PUNCT
ajst-17673	88	13	m.f	m.f	PROPN
ajst-17673	88	14	.	.	PROPN
ajst-17673	88	15	fromm	fromm	PROPN
ajst-17673	88	16	,	,	PUNCT
ajst-17673	88	17	et	et	PROPN
ajst-17673	88	18	al.impact	al.impact	ADJ
ajst-17673	88	19	of	of	ADP
ajst-17673	88	20	cytochrome	cytochrome	ADJ
ajst-17673	88	21	p450	p450	PROPN
ajst-17673	88	22	2c19	2c19	NOUN
ajst-17673	88	23	loss	loss	NOUN
ajst-17673	88	24	-	-	PUNCT
ajst-17673	88	25	of	of	ADP
ajst-17673	88	26	-	-	PUNCT
ajst-17673	88	27	function	function	NOUN
ajst-17673	88	28	polymorphism	polymorphism	NOUN
ajst-17673	88	29	and	and	CCONJ
ajst-17673	88	30	of	of	ADP
ajst-17673	88	31	major	major	ADJ
ajst-17673	88	32	demographic	demographic	ADJ
ajst-17673	88	33	characteristics	characteristic	NOUN
ajst-17673	88	34	on	on	ADP
ajst-17673	88	35	residual	residual	ADJ
ajst-17673	88	36	platelet	platelet	NOUN
ajst-17673	88	37	function	function	NOUN
ajst-17673	88	38	after	after	ADP
ajst-17673	88	39	loading	loading	NOUN
ajst-17673	88	40	and	and	CCONJ
ajst-17673	88	41	maintenance	maintenance	NOUN
ajst-17673	88	42	treatment	treatment	NOUN
ajst-17673	88	43	with	with	ADP
ajst-17673	88	44	clopidogrel	clopidogrel	NOUN
ajst-17673	88	45	in	in	ADP
ajst-17673	88	46	patients	patient	NOUN
ajst-17673	88	47	undergoing	undergo	VERB
ajst-17673	88	48	elective	elective	ADJ
ajst-17673	88	49	coronary	coronary	ADJ
ajst-17673	88	50	stent	stent	NOUN
ajst-17673	88	51	placement	placement	NOUN
ajst-17673	88	52	j	j	PROPN
ajst-17673	88	53	am	be	AUX
ajst-17673	88	54	coll	coll	PROPN
ajst-17673	88	55	cardiol	cardiol	NOUN
ajst-17673	88	56	,	,	PUNCT
ajst-17673	88	57	55	55	NUM
ajst-17673	88	58	(	(	PUNCT
ajst-17673	88	59	2010	2010	NUM
ajst-17673	88	60	)	)	PUNCT
ajst-17673	88	61	,	,	PUNCT
ajst-17673	88	62	pp	pp	ADP
ajst-17673	88	63	.	.	PUNCT
ajst-17673	89	1	2427	2427	NUM
ajst-17673	89	2	-	-	SYM
ajst-17673	89	3	2434	2434	NUM
ajst-17673	89	4	[	[	X
ajst-17673	89	5	7	7	NUM
ajst-17673	89	6	]	]	X
ajst-17673	89	7	m.j	m.j	PROPN
ajst-17673	89	8	.	.	PROPN
ajst-17673	89	9	price	price	PROPN
ajst-17673	89	10	,	,	PUNCT
ajst-17673	89	11	s.s	s.s	PROPN
ajst-17673	89	12	.	.	PROPN
ajst-17673	89	13	murray	murray	PROPN
ajst-17673	89	14	,	,	PUNCT
ajst-17673	89	15	d.j	d.j	PROPN
ajst-17673	89	16	.	.	PROPN
ajst-17673	89	17	angiolillo	angiolillo	PROPN
ajst-17673	89	18	,	,	PUNCT
ajst-17673	89	19	et	et	PROPN
ajst-17673	89	20	al	al	PROPN
ajst-17673	89	21	.	.	PUNCT
ajst-17673	89	22	influence	influence	NOUN
ajst-17673	89	23	of	of	ADP
ajst-17673	89	24	genetic	genetic	ADJ
ajst-17673	89	25	polymorphisms	polymorphism	NOUN
ajst-17673	89	26	on	on	ADP
ajst-17673	89	27	the	the	DET
ajst-17673	89	28	effect	effect	NOUN
ajst-17673	89	29	of	of	ADP
ajst-17673	89	30	highand	highand	ADJ
ajst-17673	89	31	standarddose	standarddose	VERB
ajst-17673	89	32	clopidogrel	clopidogrel	NOUN
ajst-17673	89	33	after	after	ADP
ajst-17673	89	34	percutaneous	percutaneous	ADJ
ajst-17673	89	35	coronary	coronary	ADJ
ajst-17673	89	36	intervention	intervention	NOUN
ajst-17673	89	37	:	:	PUNCT
ajst-17673	89	38	the	the	DET
ajst-17673	89	39	gift	gift	NOUN
ajst-17673	89	40	(	(	PUNCT
ajst-17673	89	41	genotype	genotype	NOUN
ajst-17673	89	42	information	information	NOUN
ajst-17673	89	43	and	and	CCONJ
ajst-17673	89	44	functional	functional	ADJ
ajst-17673	89	45	testing	testing	NOUN
ajst-17673	89	46	)	)	PUNCT
ajst-17673	89	47	study	study	NOUN
ajst-17673	89	48	j	j	PROPN
ajst-17673	89	49	am	be	AUX
ajst-17673	89	50	coll	coll	PROPN
ajst-17673	89	51	cardiol	cardiol	PROPN
ajst-17673	89	52	,	,	PUNCT
ajst-17673	89	53	59	59	NUM
ajst-17673	89	54	(	(	PUNCT
ajst-17673	89	55	2012	2012	NUM
ajst-17673	89	56	)	)	PUNCT
ajst-17673	89	57	,	,	PUNCT
ajst-17673	89	58	pp	pp	ADP
ajst-17673	89	59	.	.	PUNCT
ajst-17673	89	60	1928	1928	NUM
ajst-17673	89	61	-	-	SYM
ajst-17673	89	62	1937	1937	NUM
ajst-17673	90	1	[	[	X
ajst-17673	90	2	8	8	NUM
ajst-17673	90	3	]	]	X
ajst-17673	90	4	wallentin	wallentin	NOUN
ajst-17673	90	5	l	l	PROPN
ajst-17673	90	6	,	,	PUNCT
ajst-17673	90	7	becker	becker	PROPN
ajst-17673	90	8	rc	rc	PROPN
ajst-17673	90	9	,	,	PUNCT
ajst-17673	90	10	budaj	budaj	VERB
ajst-17673	90	11	a	a	PRON
ajst-17673	90	12	,	,	PUNCT
ajst-17673	90	13	et	et	PROPN
ajst-17673	90	14	al	al	PROPN
ajst-17673	90	15	.	.	PROPN
ajst-17673	90	16	ticagrelor	ticagrelor	NOUN
ajst-17673	90	17	versus	versus	ADP
ajst-17673	90	18	clopidogrel	clopidogrel	NOUN
ajst-17673	90	19	in	in	ADP
ajst-17673	90	20	patients	patient	NOUN
ajst-17673	90	21	with	with	ADP
ajst-17673	90	22	acute	acute	ADJ
ajst-17673	90	23	coronary	coronary	ADJ
ajst-17673	90	24	syndromes	syndrome	NOUN
ajst-17673	90	25	.	.	PUNCT
ajst-17673	91	1	n	n	PROPN
ajst-17673	91	2	engl	engl	PROPN
ajst-17673	91	3	j	j	PROPN
ajst-17673	91	4	med	me	VERB
ajst-17673	91	5	2009;361:1045	2009;361:1045	NUM
ajst-17673	91	6	-	-	SYM
ajst-17673	91	7	57	57	NUM
ajst-17673	91	8	.	.	PUNCT
ajst-17673	92	1	[	[	X
ajst-17673	92	2	9	9	NUM
ajst-17673	92	3	]	]	X
ajst-17673	92	4	wiviott	wiviott	NOUN
ajst-17673	92	5	sd	sd	PROPN
ajst-17673	92	6	,	,	PUNCT
ajst-17673	92	7	braunwald	braunwald	PROPN
ajst-17673	92	8	e	e	NOUN
ajst-17673	92	9	,	,	PUNCT
ajst-17673	92	10	mccabe	mccabe	PROPN
ajst-17673	92	11	ch	ch	PROPN
ajst-17673	92	12	,	,	PUNCT
ajst-17673	92	13	et	et	PROPN
ajst-17673	92	14	al	al	PROPN
ajst-17673	92	15	.	.	PROPN
ajst-17673	92	16	prasugrel	prasugrel	NOUN
ajst-17673	92	17	versus	versus	ADP
ajst-17673	92	18	clopidogrel	clopidogrel	NOUN
ajst-17673	92	19	in	in	ADP
ajst-17673	92	20	patients	patient	NOUN
ajst-17673	92	21	with	with	ADP
ajst-17673	92	22	acute	acute	ADJ
ajst-17673	92	23	coronary	coronary	ADJ
ajst-17673	92	24	syndromes	syndrome	NOUN
ajst-17673	92	25	.	.	PUNCT
ajst-17673	93	1	n	n	PROPN
ajst-17673	93	2	engl	engl	PROPN
ajst-17673	93	3	j	j	PROPN
ajst-17673	93	4	med	med	PROPN
ajst-17673	93	5	2007;357:2001	2007;357:2001	PROPN
ajst-17673	93	6	-	-	SYM
ajst-17673	93	7	15	15	NUM
ajst-17673	93	8	.	.	PUNCT
ajst-17673	94	1	[	[	X
ajst-17673	94	2	10	10	NUM
ajst-17673	94	3	]	]	SYM
ajst-17673	94	4	sd	sd	NOUN
ajst-17673	94	5	wiviott	wiviott	NOUN
ajst-17673	94	6	,	,	PUNCT
ajst-17673	94	7	e	e	PROPN
ajst-17673	94	8	braunwald	braunwald	PROPN
ajst-17673	94	9	,	,	PUNCT
ajst-17673	94	10	ch	ch	PROPN
ajst-17673	94	11	mccabe	mccabe	PROPN
ajst-17673	94	12	,	,	PUNCT
ajst-17673	94	13	et	et	PROPN
ajst-17673	94	14	al.prasugrel	al.prasugrel	X
ajst-17673	94	15	versus	versus	ADP
ajst-17673	94	16	clopidogrel	clopidogrel	NOUN
ajst-17673	94	17	in	in	ADP
ajst-17673	94	18	patients	patient	NOUN
ajst-17673	94	19	with	with	ADP
ajst-17673	94	20	acute	acute	ADJ
ajst-17673	94	21	coronary	coronary	ADJ
ajst-17673	94	22	syndromesn	syndromesn	NOUN
ajst-17673	94	23	engl	engl	PROPN
ajst-17673	94	24	j	j	PROPN
ajst-17673	94	25	med	med	PROPN
ajst-17673	94	26	,	,	PUNCT
ajst-17673	94	27	357	357	NUM
ajst-17673	94	28	(	(	PUNCT
ajst-17673	94	29	2007	2007	NUM
ajst-17673	94	30	)	)	PUNCT
ajst-17673	94	31	,	,	PUNCT
ajst-17673	94	32	pp	pp	ADP
ajst-17673	94	33	.	.	PUNCT
ajst-17673	95	1	2001	2001	NUM
ajst-17673	95	2	-	-	SYM
ajst-17673	95	3	2015	2015	NUM
ajst-17673	95	4	97	97	NUM
ajst-17673	96	1	[	[	SYM
ajst-17673	96	2	11	11	NUM
ajst-17673	96	3	]	]	PUNCT
ajst-17673	96	4	l	l	NOUN
ajst-17673	96	5	wallentin	wallentin	NOUN
ajst-17673	96	6	,	,	PUNCT
ajst-17673	96	7	rc	rc	PROPN
ajst-17673	96	8	becker	becker	PROPN
ajst-17673	96	9	,	,	PUNCT
ajst-17673	96	10	a	a	DET
ajst-17673	96	11	budaj	budaj	NOUN
ajst-17673	96	12	,	,	PUNCT
ajst-17673	96	13	et	et	NOUN
ajst-17673	96	14	al.ticagrelor	al.ticagrelor	X
ajst-17673	96	15	versus	versus	ADP
ajst-17673	96	16	clopidogrel	clopidogrel	NOUN
ajst-17673	96	17	in	in	ADP
ajst-17673	96	18	patients	patient	NOUN
ajst-17673	96	19	with	with	ADP
ajst-17673	96	20	acute	acute	ADJ
ajst-17673	96	21	coronary	coronary	ADJ
ajst-17673	96	22	syndromes	syndrome	NOUN
ajst-17673	96	23	n	n	PRON
ajst-17673	96	24	engl	engl	PROPN
ajst-17673	96	25	j	j	PROPN
ajst-17673	96	26	med	med	PROPN
ajst-17673	96	27	,	,	PUNCT
ajst-17673	96	28	361	361	NUM
ajst-17673	96	29	(	(	PUNCT
ajst-17673	96	30	2009	2009	NUM
ajst-17673	96	31	)	)	PUNCT
ajst-17673	96	32	,	,	PUNCT
ajst-17673	96	33	pp	pp	ADP
ajst-17673	96	34	.	.	PUNCT
ajst-17673	97	1	1045	1045	NUM
ajst-17673	97	2	-	-	SYM
ajst-17673	97	3	1057	1057	NUM
ajst-17673	97	4	[	[	X
ajst-17673	97	5	12	12	NUM
ajst-17673	97	6	]	]	X
ajst-17673	97	7	r	r	NOUN
ajst-17673	97	8	piccolo	piccolo	NOUN
ajst-17673	97	9	,	,	PUNCT
ajst-17673	97	10	g	g	PROPN
ajst-17673	97	11	magnani	magnani	X
ajst-17673	97	12	,	,	PUNCT
ajst-17673	97	13	s	s	VERB
ajst-17673	97	14	ariotti	ariotti	PROPN
ajst-17673	97	15	,	,	PUNCT
ajst-17673	97	16	et	et	PROPN
ajst-17673	97	17	al.ischaemic	al.ischaemic	ADJ
ajst-17673	97	18	and	and	CCONJ
ajst-17673	97	19	bleeding	bleed	VERB
ajst-17673	97	20	outcomes	outcome	NOUN
ajst-17673	97	21	in	in	ADP
ajst-17673	97	22	elderly	elderly	ADJ
ajst-17673	97	23	patients	patient	NOUN
ajst-17673	97	24	undergoing	undergo	VERB
ajst-17673	97	25	a	a	DET
ajst-17673	97	26	prolonged	prolonged	ADJ
ajst-17673	97	27	versus	versus	ADP
ajst-17673	97	28	shortened	shorten	VERB
ajst-17673	97	29	duration	duration	NOUN
ajst-17673	97	30	of	of	ADP
ajst-17673	97	31	dual	dual	ADJ
ajst-17673	97	32	antiplatelet	antiplatelet	NOUN
ajst-17673	97	33	therapy	therapy	NOUN
ajst-17673	97	34	after	after	ADP
ajst-17673	97	35	percutaneous	percutaneous	ADJ
ajst-17673	97	36	coronary	coronary	ADJ
ajst-17673	97	37	intervention	intervention	NOUN
ajst-17673	97	38	:	:	PUNCT
ajst-17673	97	39	insights	insight	NOUN
ajst-17673	97	40	from	from	ADP
ajst-17673	97	41	the	the	DET
ajst-17673	97	42	prodigy	prodigy	NOUN
ajst-17673	97	43	randomised	randomise	VERB
ajst-17673	97	44	trial	trial	NOUN
ajst-17673	97	45	eurointervention	eurointervention	NOUN
ajst-17673	97	46	,	,	PUNCT
ajst-17673	97	47	13	13	NUM
ajst-17673	97	48	(	(	PUNCT
ajst-17673	97	49	2017	2017	NUM
ajst-17673	97	50	)	)	PUNCT
ajst-17673	97	51	,	,	PUNCT
ajst-17673	97	52	pp	pp	ADJ
ajst-17673	97	53	.	.	PUNCT
ajst-17673	98	1	78	78	NUM
ajst-17673	98	2	-	-	SYM
ajst-17673	98	3	86	86	NUM
ajst-17673	99	1	[	[	X
ajst-17673	99	2	13	13	NUM
ajst-17673	99	3	]	]	SYM
ajst-17673	99	4	j	j	PROPN
ajst-17673	99	5	chandrasekhar	chandrasekhar	PROPN
ajst-17673	99	6	,	,	PUNCT
ajst-17673	99	7	u	u	PROPN
ajst-17673	99	8	baber	baber	PROPN
ajst-17673	99	9	,	,	PUNCT
ajst-17673	99	10	s	s	PROPN
ajst-17673	99	11	sartori	sartori	NOUN
ajst-17673	99	12	,	,	PUNCT
ajst-17673	99	13	et	et	NOUN
ajst-17673	99	14	al.prasugrel	al.prasugrel	NOUN
ajst-17673	99	15	use	use	VERB
ajst-17673	99	16	and	and	CCONJ
ajst-17673	99	17	clinical	clinical	ADJ
ajst-17673	99	18	outcomes	outcome	NOUN
ajst-17673	99	19	by	by	ADP
ajst-17673	99	20	age	age	NOUN
ajst-17673	99	21	among	among	ADP
ajst-17673	99	22	patients	patient	NOUN
ajst-17673	99	23	undergoing	undergo	VERB
ajst-17673	99	24	pci	pci	ADJ
ajst-17673	99	25	for	for	ADP
ajst-17673	99	26	acute	acute	ADJ
ajst-17673	99	27	coronary	coronary	ADJ
ajst-17673	99	28	syndrome	syndrome	NOUN
ajst-17673	99	29	:	:	PUNCT
ajst-17673	99	30	from	from	ADP
ajst-17673	99	31	the	the	DET
ajst-17673	99	32	prometheus	prometheus	PROPN
ajst-17673	99	33	studyclin	studyclin	PROPN
ajst-17673	99	34	res	res	PROPN
ajst-17673	99	35	cardiol	cardiol	NOUN
ajst-17673	99	36	(	(	PUNCT
ajst-17673	99	37	2020	2020	NUM
ajst-17673	99	38	)	)	PUNCT
ajst-17673	99	39	published	publish	VERB
ajst-17673	99	40	online	online	ADJ
ajst-17673	99	41	january	january	PROPN
ajst-17673	99	42	8	8	NUM
ajst-17673	99	43	.	.	PUNCT
ajst-17673	100	1	[	[	X
ajst-17673	100	2	14	14	NUM
ajst-17673	100	3	]	]	PUNCT
ajst-17673	100	4	capodanno	capodanno	NOUN
ajst-17673	100	5	d	d	PROPN
ajst-17673	100	6	,	,	PUNCT
ajst-17673	100	7	alfonso	alfonso	PROPN
ajst-17673	100	8	f	f	PROPN
ajst-17673	100	9	,	,	PUNCT
ajst-17673	100	10	levine	levine	PROPN
ajst-17673	100	11	gn	gn	PROPN
ajst-17673	100	12	,	,	PUNCT
ajst-17673	100	13	et	et	PROPN
ajst-17673	100	14	al	al	PROPN
ajst-17673	100	15	.	.	PROPN
ajst-17673	100	16	acc	acc	PROPN
ajst-17673	100	17	/	/	PROPN
ajst-17673	100	18	aha	aha	PROPN
ajst-17673	100	19	versus	versus	ADP
ajst-17673	100	20	esc	esc	NOUN
ajst-17673	100	21	guidelines	guideline	NOUN
ajst-17673	100	22	on	on	ADP
ajst-17673	100	23	dual	dual	ADJ
ajst-17673	100	24	antiplatelet	antiplatelet	NOUN
ajst-17673	100	25	therapy	therapy	NOUN
ajst-17673	100	26	:	:	PUNCT
ajst-17673	100	27	jacc	jacc	PROPN
ajst-17673	100	28	guideline	guideline	NOUN
ajst-17673	100	29	comparison[j	comparison[j	PROPN
ajst-17673	100	30	]	]	PUNCT
ajst-17673	100	31	.	.	PUNCT
ajst-17673	101	1	j	j	PROPN
ajst-17673	101	2	am	be	AUX
ajst-17673	101	3	coll	coll	PROPN
ajst-17673	101	4	cardiol	cardiol	NOUN
ajst-17673	101	5	,	,	PUNCT
ajst-17673	101	6	2018	2018	NUM
ajst-17673	101	7	,	,	PUNCT
ajst-17673	101	8	72(23pt	72(23pt	PROPN
ajst-17673	101	9	a	a	PRON
ajst-17673	101	10	):	):	PUNCT
ajst-17673	101	11	29152931	29152931	NUM
ajst-17673	101	12	.	.	PUNCT
ajst-17673	102	1	doi	doi	NOUN
ajst-17673	102	2	:	:	PUNCT
ajst-17673	102	3	10.1016	10.1016	NUM
ajst-17673	102	4	/	/	SYM
ajst-17673	102	5	j.jacc.2018.09.057	j.jacc.2018.09.057	PROPN
ajst-17673	102	6	.	.	PUNCT
ajst-17673	103	1	[	[	X
ajst-17673	103	2	15	15	NUM
ajst-17673	103	3	]	]	PUNCT
ajst-17673	103	4	gorog	gorog	NOUN
ajst-17673	103	5	da	da	PROPN
ajst-17673	103	6	,	,	PUNCT
ajst-17673	103	7	yamamoto	yamamoto	PROPN
ajst-17673	103	8	j	j	PROPN
ajst-17673	103	9	,	,	PUNCT
ajst-17673	103	10	saraf	saraf	PROPN
ajst-17673	103	11	s	s	PROPN
ajst-17673	103	12	,	,	PUNCT
ajst-17673	103	13	et	et	PROPN
ajst-17673	103	14	al	al	PROPN
ajst-17673	103	15	.	.	PUNCT
ajst-17673	104	1	first	first	PROPN
ajst-17673	104	2	direct	direct	ADJ
ajst-17673	104	3	comparison	comparison	NOUN
ajst-17673	104	4	of	of	ADP
ajst-17673	104	5	platelet	platelet	NOUN
ajst-17673	104	6	reactivity	reactivity	NOUN
ajst-17673	104	7	and	and	CCONJ
ajst-17673	104	8	thrombolytic	thrombolytic	ADJ
ajst-17673	104	9	status	status	NOUN
ajst-17673	104	10	between	between	ADP
ajst-17673	104	11	japanese	japanese	ADJ
ajst-17673	104	12	and	and	CCONJ
ajst-17673	104	13	western	western	ADJ
ajst-17673	104	14	volunteers	volunteer	NOUN
ajst-17673	104	15	:	:	PUNCT
ajst-17673	104	16	possible	possible	ADJ
ajst-17673	104	17	relationship	relationship	NOUN
ajst-17673	104	18	to	to	ADP
ajst-17673	104	19	the	the	DET
ajst-17673	104	20	"	"	PUNCT
ajst-17673	104	21	japanese	japanese	PROPN
ajst-17673	104	22	paradox"[j	paradox"[j	X
ajst-17673	104	23	]	]	PUNCT
ajst-17673	104	24	.	.	PUNCT
ajst-17673	105	1	int	int	PROPN
ajst-17673	105	2	j	j	PROPN
ajst-17673	105	3	cardiol	cardiol	NOUN
ajst-17673	105	4	,	,	PUNCT
ajst-17673	105	5	2011	2011	NUM
ajst-17673	105	6	,	,	PUNCT
ajst-17673	105	7	152(1	152(1	NUM
ajst-17673	105	8	):	):	PUNCT
ajst-17673	105	9	43	43	NUM
ajst-17673	105	10	-	-	SYM
ajst-17673	105	11	48	48	NUM
ajst-17673	105	12	.	.	PUNCT
ajst-17673	106	1	doi	doi	NOUN
ajst-17673	106	2	:	:	PUNCT
ajst-17673	106	3	10.1016	10.1016	NUM
ajst-17673	106	4	/	/	SYM
ajst-17673	106	5	j.ijcard.2010.07.002	j.ijcard.2010.07.002	NOUN
ajst-17673	106	6	.	.	PUNCT
ajst-17673	107	1	[	[	X
ajst-17673	107	2	16	16	NUM
ajst-17673	107	3	]	]	X
ajst-17673	107	4	thomas	thomas	PROPN
ajst-17673	107	5	mp	mp	PROPN
ajst-17673	107	6	,	,	PUNCT
ajst-17673	107	7	moscucci	moscucci	PROPN
ajst-17673	107	8	m	m	PROPN
ajst-17673	107	9	,	,	PUNCT
ajst-17673	107	10	smith	smith	PROPN
ajst-17673	107	11	de	de	PROPN
ajst-17673	107	12	,	,	PUNCT
ajst-17673	107	13	et	et	PROPN
ajst-17673	107	14	al	al	PROPN
ajst-17673	107	15	.	.	PROPN
ajst-17673	107	16	outcome	outcome	NOUN
ajst-17673	107	17	of	of	ADP
ajst-17673	107	18	contemporary	contemporary	ADJ
ajst-17673	107	19	percutaneous	percutaneous	ADJ
ajst-17673	107	20	coronary	coronary	ADJ
ajst-17673	107	21	intervention	intervention	NOUN
ajst-17673	107	22	in	in	ADP
ajst-17673	107	23	the	the	DET
ajst-17673	107	24	elderly	elderly	ADJ
ajst-17673	107	25	and	and	CCONJ
ajst-17673	107	26	the	the	DET
ajst-17673	107	27	very	very	ADV
ajst-17673	107	28	elderly	elderly	ADJ
ajst-17673	107	29	:	:	PUNCT
ajst-17673	107	30	insights	insight	NOUN
ajst-17673	107	31	from	from	ADP
ajst-17673	107	32	the	the	DET
ajst-17673	107	33	blue	blue	PROPN
ajst-17673	107	34	cross	cross	NOUN
ajst-17673	107	35	blue	blue	ADJ
ajst-17673	107	36	shield	shield	NOUN
ajst-17673	107	37	of	of	ADP
ajst-17673	107	38	michigan	michigan	PROPN
ajst-17673	107	39	cardiovascular	cardiovascular	PROPN
ajst-17673	107	40	consortium[j	consortium[j	PROPN
ajst-17673	107	41	]	]	PUNCT
ajst-17673	107	42	.	.	PUNCT
ajst-17673	108	1	clin	clin	PROPN
ajst-17673	108	2	cardiol	cardiol	PROPN
ajst-17673	108	3	,	,	PUNCT
ajst-17673	108	4	2011	2011	NUM
ajst-17673	108	5	,	,	PUNCT
ajst-17673	108	6	34(9	34(9	NUM
ajst-17673	108	7	):	):	PUNCT
ajst-17673	108	8	549	549	NUM
ajst-17673	108	9	-	-	SYM
ajst-17673	108	10	554	554	NUM
ajst-17673	108	11	.	.	PUNCT
ajst-17673	109	1	doi	doi	NOUN
ajst-17673	109	2	:	:	PUNCT
ajst-17673	109	3	10.1002	10.1002	NUM
ajst-17673	109	4	/	/	SYM
ajst-17673	109	5	clc.20926	clc.20926	NOUN
ajst-17673	109	6	.	.	PUNCT